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Angiomotin is a novel cadherin-11 interacting protein that mediates
migration in prostate cancer cells

Angelica Ortiz, B.A., M.A.
Supervisory Professor: Sue-Hwa Lin, Ph.D.

Prostate cancer (PCa), the second leading cause of cancer-related deaths among men
in the United States, has the proclivity to metastasize to bone resulting in sclerotic lesions.
These cancer induced bone growths cause bone pain and fractures. Therefore, understanding
the molecular mechanisms contributing to PCa bone metastasis is required in order to find
better prognostic tools and suitable targets for metastasis treatment and/ or prevention.
Previous work in our laboratory showed increased expression of cadherin-11 (Cad11), a
mesenchymal cadherin, during PCa progression. Furthermore, Cad11 expression endows
PCa cells with increased migratory potential and metastasis to bone. Deletion of the Cad11
cytoplasmic region (cyto) resulted in loss of cell migration. How the Cad11 cytoplasmic
domain mediates cell migration is unknown. We have identified angiomotin (Amot), a regulator

of endothelial cell migration and epithelial cell polarity, as a Cad11 interacting protein.
Deletion analysis showed that the last C-terminal 10 amino acids in Cad11 mediated Amot
binding. Further, Cad11 preferentially interacts with the Amot-p80 isoform than the Amotp130. Analysis of Amot mutants showed that Amot-p80 interacts with Cad11 through its
middle domain, not the well characterized coiled-coil domains or PDZ motif. Deletion of the
last ten Cad11 residues significantly reduced Cad11-mediated cell migration in C4-2B4,
PC3-mm2, and HEK293T cells, compared to cells expressing wild-type Cad11. Together,
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our studies identified and characterized Amot-p80 as a novel Cad11 binding protein that
promotes Cad11-mediated PCa cell migration.
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Chapter I: Background and Significance

Prostate Cancer (PCa)

PCa is the most commonly diagnosed cancer and second leading cause of cancer
related death among American males3. PCa tumors are relatively slow-growing masses,
therefore, it may be years before the prostate becomes large enough for detection thereby
giving the cancerous cells time and opportunity to metastasize; unlike in patients with benign
prostatic hyperplasia (BPH) whose prostates become so enlarged that pain is quickly felt for
expedient diagnosis. In fact, upon diagnosis, most men with PCa present a Gleason sum of
6-7, with 2 representing normal prostate and 10 representing and extremely aggressive cancer
2

. Thus, there is a need for identification of biomarkers for early detection and accurate

prognosis.
In an effort to circumvent metastatic incidence and detect PCa at earlier stages, there
have been studies focusing to identify markers from tissue, blood, and/or urine that can be
used as diagnostic and prognostic factors. The most notable are the measurement of prostatic
acid phosphatase (PAP) and prostate specific antigen (PSA).

PAP is a glycoprotein

predominately produced by the prostate. PAP in the serum was an indicator of metastasis,
but was insufficiently sensitive to detect localized disease127.

Focus was then lent to

optimizing techniques to measure levels of PSA in serum. PSA is a glycoprotein enzyme
secreted by the epithelial cells of the prostate gland. PSA is present in small concentrations
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in the serum of healthy males, but is elevated in presence of PCa and other prostate disorders,
as well as changes in medications and environment127. Moreover, PSA levels could not
distinguish between PCa stages nor was it a good indicator of metastatic lesions127. Since the
implementation of the PSA test, PCa mortality has decreased, however, there is insufficient
evidence that this decrease is due to the accuracy of the PSA test, especially because of the
false positives generated127. As such, metastasis of the disease remains a concern in the
diagnosis and treatment of PCa patients.

Prostate Cancer Metastasis and the Bone Microenvironment

Bone metastasis is the main cause of morbidity and mortality in patients suffering
from advanced PCa104, 122. After cancer cells disseminate from the primary site, they must
enter the vasculature, survive the shearing forces in circulation, and exit circulation to
colonize a distant site that provides an environment amenable to promote cancer cell survival
and proliferation87. Clinical observations and studies have shown that cancers of certain
tissue origin have a pattern of metastasis to multiple sites87.

Interestingly, PCa

predominantly metastasizes to bone with lesions appearing in the vertebra and ribs22, 104, 105,
108

. The PCa cells disseminate from the primary tumor to then enter the Batson’s venous

plexus, a valveless network of veins that connects the deep pelvic veins to the internal
vertebral venous plexus, thereby facilitating metastasis to bone 78.
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Once in the bone, invading cancer cells can either activate or inhibit the activity of
bone stromal cells called osteoblasts and osteoclasts. Osteoblasts are responsible for the
secretion of bone matrix and subsequent mineralization needed to form new bone75.
Osteoclasts lyse mineralized bone, in a process called resorption, in order to maintain shape
but also in response to stimuli, such as loss of mechanical loading, low blood calcium, or
changes in cytokine/hormone serum levels75. The bone metastatic lesions resulting from
tumor burden, which induce increased osteoclast activity, are called osteolytic, while those
that result in increased osteoblast activity are called osteoblastic or sclerotic.
Under normal conditions, the processes of resorbing and forming bone are coupled
and highly regulated to maintain skeletal integrity under changing physiological conditions.
When cancer cells invade the bone microenvironment, this coupling is distorted resulting in
increased osteolytic or osteoblastic activity. Multiple myeloma cells in the bone secrete
factors resulting in osteolytic metastatic lesions102. Breast cancer (BCa) metastatic lesions,
though predominantly osteolytic in phenotype, have been observed to present a mixed
osteoblastic and osteolytic phenotype102.
Unlike other bone tropic cancers, PCa is uniquely and predominantly osteoblastic71.
Post-mortem analysis showed that approximately 60 to 80% of men with PCa have bone
forming masses22, 38, 78. Histological analyses found PCa cells surrounded by newly formed
bone104. Studies have shown that the osteoblastic masses found are a result of PCa cells
secreting proteins that increase the proliferation and differentiation of osteoblasts resulting in
the fast formation of new bone, such as BMP-463. This newly formed bone, also called
woven bone, is not tightly regulated by normal bone resorption/absorption mechanisms
resulting in haphazard organization of collagen fibers creating dense patches of sclerotic
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lesions that are mechanically weak thereby leading to bone fractures and pain57, 80. The cause
of the frail skeleton in patients with osteoblastic lesions may be the heterogeneity within the
lesions that present both osteopenic and osteodense patches as determined by
histomorphometric analysis of metastatic biopsy105. This new PCa cell/osteoblast coupling
results in favorable conditions not only for osteoblasts, but for PCa cells as well.
Osteoblasts secrete factors that assist in PCa cell survival within the bone as well as
promote PCa cell proliferation. Co-culture assays using primary mouse osteoblasts and PCa
cells have shown osteoblasts secrete osteopontin to affect cell survival, and sialoprotein to
increase PCa cell affinity to bone29.

Osteoblasts also promote PCa growth indirectly.

Formation of the new bone induces systemic repercussions because in making the new bone,
nutrients are pulled in from the blood, which leads to hypocalcemia and other nutritional
deficiencies80,

98, 118

.

The resulting hypocalcemia induces secretion of the parathyroid

hormone leading to the secretion of receptor activator of nuclear factor kappa-B ligand
(RANKL) in the bone marrow stromal cells and PCa cells to promote osteoclast
differentiation and activation57, 61, 85. This osteoclast activation may be an attempt to balance
the high bone forming rate. However, the resulting osteolysis results in the release of growth
factors from bone that aid in PCa cell growth94. Thus, PCa invasion of the bone results in a
vicious cycle between the PCa cells and the bone stromal cells. Therefore, it is important to
identify proteins and signaling pathways contributing to PCa metastasis to bone and promote
PCa growth in the bone that may be used to identify therapeutic targets to block or
specifically treat these skeletal masses, as well as identify novel diagnostic/prognostic
markers.
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Treatment and Prevention of Bone Metastasis

Observing the role of osteoclast activation in promoting PCa bone metastasis,
treatment strategies used for osteolytic cancers, such as multiple myeloma, were
implemented for PCa patients.

Treatments that target osteoclast activation include

administration of bisphosphonates, such as zoledronic acid, and monoclonal antibodies, such
as Denosumab, which have been successful in treating cancer patients with osteolytic
metastatic lesions90,

146

.

It was believed that suppressing the osteoclast activity in the

PCa/bone microenvironment vicious cycle would yield similar effects in PCa patients.
In multiple myeloma, treatment with zoledronic acid, a potent synthetic analog of
pyrophosphate, is able to reduce osteolytic markers, skeletal related events, and improve
overall survival79. Though zoledronic acid treatment did show a reduction in bone pain for
some PCa patients, they found greater efficacy when administered prior to the existence of
bone pain106.

Moreover, there was little benefit in overall PCa patient survival106.

Histopathologic analyses of PCa patient bone lesions by Roudier et al found that treatment
with bisphosphonates changed little of the overall bone/tumor architecture105. To understand
this underwhelming outcome for the use of zoledronic acid in treating PCa, Thudi et al
injected canine prostate cancer cells into nude mice then treated with zoledronic acid122. The
cancer cells generated mixed osteoblastic and osteolytic lesions, and, while treatment with
zoledronic acid did reduce osteolysis, it had no significant effect on osteoblastic activity122.
These studies suggest that perhaps this method of targeting PCa cell interaction with the bone
microenvironment was not an efficacious strategy94.

6

In a different strategy to target osteoclast activity to reduce PCa tumor burden in the
bone, the human monoclonal IgG2 antibody against RANKL, called Denosumab, was used.
Denosumab is administered every six months with a dose of 60mg with the purpose of
preventing bone loss and fractures.

Some clinical trials showed improvement in bone

mineral density in patients with nonmetastatic breast cancer and prostate cancer after
hormone deprivation therapy69. Though bone fractures are a concern for a patient’s overall
quality of life, suppressing osteoclast activity in PCa using Denosumab results in severe
hypocalcemia and vitamin D deficiency82.

Together this further shows that while

suppressing osteoclast activity in osteolytic bone metastasis in BCa and multiple myeloma is
effective, treatment of PCa would need to disturb either the PCa/osteoblast interaction or
prevent PCa from exiting the prostate and entering the bone microenvironment.
Once PCa metastasis occurs, effective treatment strategies are limited and shift from
curative to palliative, therefore designing strategies for prevention are needed to improve
patient care78,

95

. At the time of diagnosis, PCa patients have tumors that are hormone

dependent so are subsequently subjected to androgen ablation treatment, by either surgical or
pharmacological castration, in order to reduce testosterone levels in the blood circulation95.
Androgen ablation has been shown to decrease PCa cell proliferation and increase
apoptosis76. Moreover, this treatment resulted in remission for almost 70% of patients76.
However, this patient response does not last long and the relapsing tumor is able to thrive
independent of androgen, thus called castration resistant14, 62, 95. The resulting tumor relapse
is found in the bone in more than 80% of cases78, 95. Though hormone deprivation therapy in
treatment of PCa while still localized in the primary site seems to be highly effective, the risk
of relapse is coupled by the emergence of a more aggressive cancer. Therefore, elucidating
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the mechanisms by which PCa cells are able to disseminate from the primary site can help
identify the proteins that mediate metastasis. In turn, further study of these proteins could be
used as targets for developing novel therapies. Previous studies suggest proteins involved in
epithelial-mesenchymal transition (EMT) may be a mechanism contributing to the
progression of prostate cancer 55.

Epithelial-Mesenchymal Transition (EMT)

During development, epigenetic signals induce embryonic cells to undergo numerous
rounds of EMT and mesenchymal-epithelial transition (MET) to form complex tissue
architectures120,

121

. As cells undergo EMT, the cell polarity needed to maintain tissue

architecture is lost and the once differentiated epithelial cells begin to have similar
morphology to stromal cells55, 121. As the cells lose their epithelial cell markers, they begin to
upregulate several transcription factors, such as Snail, Slug, and Twist88.

In MET,

mesenchymal cells express epithelial proteins to reestablish apical polarity and cell-cell
contacts55, 144. These transitions are not irreversible, therefore, even in adult tissue, epithelial
cells maintain cellular plasticity governed by various cellular and molecular events55, 120, 121,
144

. And it is this plasticity that aids in cancer cell adaptation to a variety of physiological

changes.
In differentiated tissue, EMT can be induced by mechanical injury, chronic
inflammation, and molecular abnormalities resulting in upregulation of mesenchymal
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molecules and downregulation of epithelial cell molecules120, 121. These molecular variations
are tightly regulated and result in changes to cellular phenotype and tissue architecture.
However, under conditions of serious injury and excessive inflammation, deregulation of
EMT can result in the formation fibrosis or promote cancer progression. Once cancer cells
begin expression of mesenchymal proteins, we observe changes not only in morphology, but
also cellular function55, 83, 113, 120. The upregulation of Snail during EMT, for example, results
in conferring cancer cells with stem cell-like properties and increased metastatic potential130.
A hallmark of EMT during cancer progression is the loss of E-Cad and an
upregulation of mesenchymal molecules, such as mesenchymal cadherins in a process called
“cadherin switching”113, 133. The expression of mesenchymal cadherins causes alterations in
cellular phenotypes, such as loss of cell polarity, changes in cell morphology, and increased
cell migration.

Understanding how cadherin switching affects the cell can help in

understanding the role of cadherin switching in EMT and PCa progression.

Cadherins and Cadherin Switching

The cadherin superfamily is a family of transmembrane glycoproteins involved in
Ca2+-dependent cell-cell interactions and the maintenance of tissue integrity and
morphogenesis.

The cadherin cell adhesion molecules are classified into three groups:

classic cadherins, proto-cadherins, and atypical cadherins (Fig. 1)8. Cadherins known as
classic cadherins typically express 5 calcium-binding domains extracellular (EC) domains,
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while Fat, Dachsous, and proto-cadherins can possess up to 34 calcium-binding domains
(Fig. 1)8. The variety of EC domains participate in regulating homophilic and heterophilic
interactions, which mediates adhesion and cell sorting during organogenesis 42.
Classic cadherins are further classified as type I or type II. Type I cadherins possess
the HAV tripeptide motif in the first EC domain and its members include epithelial-cadherin
(E-cad), neuronal-cadherin (N-cad), placental-cadherin (P-cad) and retinal-cadherin (Rcad)42. Type II cadherins lack the HAV motif and its members include kidney-cadherin (Kcad) and osteoblast-cadherin (OB-cadherin), also known as Cad1142.

There are further

variations in the EC domains which ensure homophilic cadherin interaction and facilitate
interaction between cadherin EC domains and other proteins. For example, the N-Cad EC4
domain is able to bind the fibroblast growth factor receptor in order to activate downstream
signaling42.
The ‘classic’ cadherins express a highly conserved classical cytoplasmic region with
a juxtamembrane domain (JMD) domain and catenin binding site (CBS), which bind p120catenin (p120) and β-catenin (β-cat) respectively. The function of p120 is to stabilize the
cadherin expression and localization at the plasma membrane11, 89. Loss of p120 interaction
to the cadherin molecule would result in endocytosis of the cadherin and loss of cell
adhesion50. The role of β-cat begins as the cadherin molecule is being translated at the
endoplasmic reticulum28. There β-cat binding to the CBS aids in the stability of the cadherin
molecule for targeting to the plasma membrane28. Once at the plasma membrane, β-cat then
functions to connect the cadherin molecules to the actin cytoskeleton through interaction with
α-catenin32, 117. Though the classic cadherin cytoplasmic domains are conserved and bind
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p120 and β-cat, there is still variety within these domains that allow for protein interactions
specific to the cadherin. These unique interactions are particular to the cells that express the
cadherin8,

42

, which contribute to their unique functions in a variety of cellular and

physiological contexts in response to adhesion.
As cadherin molecules rely of homophilic adhesion for cell-cell interaction, cadherin
switching results in mesenchymal cadherin expressing cells disseminating from the
surrounding cells similar to the cell sorting observed in the organogenesis during
development42. This process may contribute to mesenchymal cadherin expressing cancer
cells escaping from the primary site and homing to a distant site populated by cells
expressing the same mesenchymal cadherin molecule. A common observation in several
cancers types is the loss of E-Cad expression and upregulation of N-Cad88,

133

. During

normal development the E-Cad to N-Cad cadherin switch is an EMT progression needed
normal embryonic development42,

120

, but N-Cad expression in cancer cells results in

increased cell migration and invasion88. Though PCa cells may express N-Cad to induce cell
migration, PCa cells have a propensity for bone metastasis. Therefore, a cadherin that would
enable interaction between PCa cells and bone stromal cells, such as Cad11, may give insight
into the molecular mechanisms that govern PCa cell migration and survival in bone.
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Figure 1. The Cadherin Superfamily. The figure shows the varying structures of the
molecules that comprise the cadherin superfamily (blue) and their common cytoplasmic
interacting proteins. Approximately 80 members of the cadherin superfamily have been
identified and classified as either classic cadherins, protocadherins, or atypical cadherins.
Classic cadherins have been identified as Cad+2-dependent cell adhesion molecules.
Cell adhesion is regulated by catenins bound to the cytoplasmic region.
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Cadherin-11 (Cad11)

The mechanisms mediating PCa preferentially metastasizing to bone are not fully
understood. Interactions of PCa cells with stromal cells present in the bone through direct
cell-cell contact and/or soluble factors secreted by PCa cells or cells in the bone
microenvironment could be contributing to this phenotype.

Hematopoietic stem cells

(HSCs), for example, are able to mobilize and home to their HSC niche utilizing cell-cell
adhesion molecules for selective retention to the niche. It is, therefore, likely that PCa cells
mimic this mechanism via cell adhesion molecules mutually expressed by PCa cells and cells
within the bone microenvironment. A gene array analysis comparing acinar and ductal PCa
patient samples, which are bone tropic and non-bone tropic respectively, identified Cad11,
also known as OB-cadherin, as a cell adhesion molecule potentially involved in
mediating/enhancing bone metastasis.
Cad11 is expressed preferentially in osteoblasts and synoviocytes60,

92

and is

associated with osteoblast differentiation58. Though Cad11 knockdown in mice did not result
in embryonic lethality, there was a reduction in bone density in the calvaria and long bone
metaphyses

56

, suggesting that Cad11 functions in osteoblast maturation

56

. Clinical PCa

specimens showed no Cad11 expression in normal prostate epithelial cells, but demonstrated
comparatively increasing levels of Cad11 expression in lymph node and bone metastasis
samples30. Moreover, our laboratory found that Cad11 was highly expressed in the bone
metastasis derived PCa cell line PC3-mm230. When injected intracardially into mice, the
PC3-mm2 cells were able to metastasize to the femur showing that PCa cells expressing
Cad11 have a preference for colonizing bone30. Furthermore, knockdown of Cad11 in PC3-
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mm2 using shRNA was able to significantly stifle the bone tropic phenotype30.

To

understand the functions that Cad11 mediates to facilitate metastasis to bone, we expressed
Cad11 in L-cells and C4-2B4 cells, and found that Cad11 expression confers cells migratory
potential, increased cell-cell adhesion, and the ability to interact with osteoblasts 47, 64. These
observations suggest that Cad11 may play a role in various key steps throughout PCa
metastasis and PCa colonization of the bone. Therefore, identification of the proteins that
specifically interact with Cad11 can be used to elucidate the mechanisms which contribute to
these unique cellular functions and how those mechanisms are regulated in PCa cells.
Moreover, these novel and unique Cad11 interacting proteins may be used as prognostic or
diagnostic markers, as well as targets for novel therapies.

Angiomotin (Amot)

Amot is a member of the Motin Family, which consists of Amot, Amot-like 1 (AmotL1), and Amot-like2 (Amot-L2)20. Amot is expressed as two isoforms via alternate splicing:
p80 and p13020,

33, 35

. Though the members of the Motin Family possess similar protein

interacting domains, such as the PDZ motif and two coiled-coil (C-C) domains, they have
varying functions20.
The p80 isoform, for example, promotes endothelial cell migration while the p130
stabilizes endothelial cell shape during tubule formation33, 35, 132. Studies have shown that
using the PDZ motif at the C-terminal, p80 is able to induce endothelial cell motility via the
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PatJ/Syx signaling complex, which directs RhoA activity to the leading edge of the migrating
cell35. The p80 isoform is able to interact with Merlin, a key component of the tumor
suppressing Hippo Pathway145 using the first C-C domain, which is rich in amphipathic
helices to promote binding to Merlin’s C-C domain via hydrophobic interactions. The AmotMerlin interaction increases Rac1-mediated migration and proliferation by releasing Rich1
from the apical complex145. Recent studies have shown that the p130 Amot isoform also
participates in the Hippo Pathway but much further downstream by promoting YAP
cytoplasmic retention to enable its phosphorylation by Lats 1/25, 65, 147 (Fig 2).
The p130 Amot isoform, as well as Amot-L1 and Amot-L2, have motifs in their Nterminals that facilitate YAP binding in the cytoplasm to inhibit YAP nuclear translocation
and transcription activity147. However, there are circumstances in which YAP transcription,
in conjunction with TEAD, is necessary to induce cellular senescence101,
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and tissue

regeneration in cardiac and pancreas tissue41; therefore, p130 expression and function need to
be regulated. The extended N-terminal expressed in p130 contains motifs that promote Amot
phosphorylation and subsequent degradation in the cell129. Another way p130 function can
be suppressed is by forming a heterodimer with the p80 isoform34. The p80 Amot isoform
utilizes its C-C domains not only to interact with other proteins, but also to form homodimers
and heterodimers with p13034.

As expression of p80 suppresses p130 function in

neovascularization, it is thought this regulation may occur through the formation of a p80p130 heterodimer34.

Together, these studies suggest an important role for Amot in

development and possibly during cancer progression.
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Figure 2. Amot
p130 plays a role
in promoting the
Hippo signaling
pathway. The
p130 Amot isoform
binds YAP through
its extended Nterminal preventing
its nuclear
translocation and
subsequent
transcriptional
function.

Cancer metastasis occurs when tumor cells lose contact inhibition, such as that
provided by p130 through the Hippo Pathway, and exhibit migratory potential, such as that
observed by p80 expression through the PatJ/Syx/RhoA complex.

In breast cancer,

upregulation of Amot transcription correlated with increased angiogenesis and poor patient
survival51. Recently, studies have shown that mouse aortic endothelial cells with increased
Amot expression resulted in more aggressive and invasive tumors66. In epithelial BCa cells,
expression of the p80 Amot isoform was shown to mediate increased cell proliferation100.
Though the functional role of the Amot isoforms in PCa cells and PCa stromal cells has not
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yet been studied, the Oncomine1 database as able to identify two independent gene array
analyses of PCa patient samples looking at molecular alterations due to hormone ablation15
and comparing primary to metastatic lesions26 that showed upregulation of Amot (Fig. 3). In
a comparison of 20 PCa patient samples, which include 10 hormone naïve and 10 hormone
refractory samples, Best et al measured changes in 12,624 genes and found Amot in the top
19% of overexpressed genes15. In a study looking at molecular differences between primary
and metastatic lesions in 31 PCa patient samples, which included 10 primary and 21
hormone-refractory metastatic lesions, Chandran et al measured changes in 14,738 genes and
also found Amot in the top 19% of overexpressed genes26.

However, neither study

distinguished between the mRNA levels of the individual isoforms, a distinction that would
allow us to understand the role of the Amot isoforms in the context of PCa.

A

B

Figure 3. Results of Oncomine database inquiry for changes in Amot mRNA levels in
independent PCa gene array analyses. (A) In 2005, Best et al found a slight increase in
Amot mRNA levels comparing hormone naïve versus hormone refractory PCa samples15.
(B) In 2007, Chandran et al found that Amot mRNA levels were higher in hormone refractory
metastatic lesions compared to primary tumor26.
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Cell Migration

Migratory potential is a necessary process in the development and maintenance of
complex, multicellular organisms. During embryonic development, wound healing, and
immune responses, cells are directed to specific locations49. Induction of cellular migration
is prompted by a variety of chemical and mechanical signals and different cells react to
different signals using different mechanisms49. Prokaryotic cells use flagella or cilia to
generate motion. Eukaryotic cell migration is vastly more complicated involving changes in
cellular shape driven by changes to the proteins that comprise the cytoskeleton resulting in
crawling or blebbing movements49. These processes are tightly regulated and errors in these
signals lead to serious consequences, such as physical deformations in fetal development and
cancer progression.
For the most part, cells migrate individually but under certain physiological
conditions a cluster of cells can migrate together in what is called collective cell migration
(Fig. 4)103, 119. The blebbing and crawling cell migration phenotypes for single cell migration
require a substrate, such as extracellular matrix (ECM), to activate integrins, which are cell
adhesion molecules that use the ECM to form focal adhesion points in order restructure the
actin cytoskeleton128. However, integrin mediated migration can be used to move across the
ECM in concert with cadherin-mediated cell-cell contacts to facilitate collective migration
(Fig. 4)103, 119.
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Figure 4. Single and Collective Cell
Migration. (A) Single cell migration
depends of ECM to engage cell
adhesion molecules in order to affect
the cell cytoskeleton; (B) Collective
cell migration can use cell-cell
contacts to induce reorganization of
the cell cytoskeleton to propel the cell
body forward. (Red line= site of
leading edge) 103.

During collective migration, both epithelial and mesenchymal cells utilize cell
adhesion molecules, such as classic cadherins, to promote coordinated movement103, 119. The
cell-cell interactions can consist of tightly or loosely associated groups of cells103. These
groups can move by forming cellular sheets, small groups, or cellular strands (Fig. 5)119.
Though epithelial tissue is generally a constrained environment that holds cells in a fixed
position by promoting apical polarity, there are conditions, as observed during
embryogenesis, that involve cell movements within a tissue sheet103.

This tissue

rearrangement is due to cadherin-mediated cell-cell adhesion complexes103. As cadherin
interaction is homophilic, neighboring cells need to express the same cadherins to engage in
coordinated migration. Coordinated migration of a cell population has been observed during
embryogenesis in the neural crest formation with N-Cad expressing cells, as well as wound
healing and cancer metastasis103, 113, 119. The cell-cell contacts formed by classic cadherins
allow the cells to exert pulling forces to generate motion of the cell body forward103.
Cell-cell interactions mediated by classic cadherins are formed in three steps:
initiation, expansion, and stabilization119. During initiation, cells move randomly throughout
the local environment using protrusions called lamellipodia to explore until they encounter a
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favorable cell-cell interaction at random119. In the expansion and stabilization steps, the cell
membranes meet and cadherins expressed on the cell surface form homophilic interactions
inducing a transient peak of Rac1 and RhoA activity to promote changes in the
cytoskeleton119.

Figure 5. Collective
Cell Migration.
Collective cell migration
mediated by classic
cadherin cell-cell
contacts can result in
cell migrating as a
sheet, as a small cluster
of cells, or as a strand
of cells.119

The eukaryotic cell cytoskeleton is comprised of actin, intermediate filaments (IFils)
and microtubules (MTs). Actin and MTs, unlike IFils, are polar structures that require ATP
or GTP hydrolysis to provide at the plus and minus ends to create unsymmetrical
polymerization and depolymerization dynamics resulting in treadmilling of the cytoskeleton
to propel the cell forward (Fig. 6)49. Changes to the actin in the cytoskeleton at specific sites
in the cell are induced by Rho proteins, which are in turn regulated by guanine nucleotide
exchange factors (GEFs) or GTPase activating proteins (GAPs)43, 115, 136. Though humans
express approximately 20 Rho GTPases, the most studied are RhoA, Rac1, and Cdc42. Rho
GTPases form protein complexes to directly or indirectly affect the assembly or disassembly
of filamentous actin (F-actin) (Fig. 6)35,

43, 115

. Studies in fibroblast cells showed Rho

activation resulted in the assembly of contractile actin-myosin filaments and associated focal
adhesion complexes, while Rac1 generated actin filament clusters to generate lamellipodia
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and Cdc42 created actin-rich protrusions called filopodia (Fig. 6)43. Presence of actin stress
fibers is a characteristic of migrating mesenchymal cells to mediate myosin II-based
contractility via associated focal adhesions125, which may be a mechanism acquired by
cancer cells during cancer-mediated EMT. Therefore, studying proteins that promote RhoA,
Cdc42, and Rac1 activity and localization of activity, such as Amot, can be candidates for
understanding the mechanisms mediating cancer cell migration.

Figure 6. Rho GTPases Reorganize Cytoskeleton. This schematic shows how the
Rho GTPases RhoA, Cdc42, and Rac1 work in concert at focal adhesion points and
the leading edge to reorganize MTOC/ MT and actin contraction to mediate cell
migration directionality. (MTOC= MT organizing center; FA=focal adhesion;
FC=Focal contact)16.
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Summary of the problem and hypothesis

PCa is the second leading cause of cancer related deaths among males living within
the United States3. Organ confined PCa tumor can be treated by surgical removal and is
sensitive to androgen deprivation therapy111. Unfortunately, once PCa metastasizes to bone,
androgen deprivation only marginally improves overall survival and as the disease becomes
castration resistant, it is no longer dependent on AR signaling for promoting PCa growth111.
Though slow growing, PCa cells secrete various factors once within the bone
microenvironment that increase osteoblast proliferation and activity to generate woven bone
resulting in pain and fractures57. This new equilibrium between the PCa cells and osteoblasts
also allows for increased PCa growth63. Treatments used for other bone tropic cancers have
limited success in admonishing this equilibrium.

Therefore, we must elucidate the

mechanisms that contribute to PCa metastasis in order to identify novel therapeutic targets
for prevention and/or treatment.
Cancer associated EMT offers a variety of signaling pathways that could contribute to
the progression of PCa disease. Loss of E-Cad expression and upregulation of Cad11 in PCa,
BCa, and renal cell carcinoma has been shown to increase cancer cell motility to promote
metastasis to bone30,

47, 97, 107

. Therefore, the identification of proteins that interact with

Cad11 in PCa cells to induce metastasis can be used as prognostic/diagnostic markers or even
possible targets in order to design novel pharmacological treatments.
The aim of this Ph.D. dissertation is to identify and characterize novel interacting
protein for the mesenchymal cadherin Cad11 that elicit changes contributing to PCa
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progression and metastasis. One of the unique properties of mesenchymal cadherins is to
increase cell migration in order to promote dissemination from the primary site to a
metastatic niche, while the epithelial cadherin (E-cadherin) has opposite effects27, 30, 97, 113.
Deletion of the Cad11 cyto domains abrogated PCa cell migration and invasion47 suggesting
intracellular signaling via one or both the Cad11 cyto domains plays a role in Cad11mediated migration. Using a protein subtraction strategy, Amot was identified as a Cad11
specific interacting protein.

Previous studies showed the p80 Amot isoform mediates

endothelial cell migration by binding to the PatJ/Syx signaling complex to concentrate RhoA
activity to the leading edge of migrating endothelial cells during neovascularization35, 123. It
is possible that expression of p80 may play a similar role in PCa cell migration. Though
previous studies have shown the contribution of Amot in development and in the
proliferation of Schwann cells145 and BCa100, this is the first endeavor to understanding the
functional role of Amot in PCa cell migration. We hypothesized that Cad11 interacts with
Amot in order to increase PCa cell migration.
In order to address and validate this hypothesis, I needed to confirm Amot as a unique
and specific Cad11 interacting protein. Then, I identified the domains or motifs that mediate
the Cad11/Amot interaction. Using human PCa cells, I showed the endogenous expression
of Amot and that the Cad11/Amot interaction is an endogenous phenomenon within the
context of PCa. Finally, I studied how the Amot/Cad11 interaction may affect Cad11mediated functions, such as cell aggregation and migration. Together this work identified
Amot as a novel Cad11 interacting protein whose function is to promote Cad11-mediated
PCa cell migration.

23

Chapter II: Materials and Methods

Cell Lines

The L-cells cell line purchased from ATCC are fibroblast cells of mouse origin. Lcells are cultured, transformed fibroblasts from mouse subcutaneous connective tissue that
express no cadherins and adhere poorly to themselves or to other cultured cells.
The HEK293 derivatives HEK293T and Phoenix cell lines were purchased from
ATCC. HEK293T cells are cultured human embryonic kidney cells transformed with SV40
T-antigen to increase transfection efficiency. Phoenix cells express Moloney Murine
Leukemia virus packaging proteins to support the production of ecotropic and amphotropic
retroviruses.
The HEK293 derivative 293FT was purchased from Life Technologies (Carlsbad,
Ca). 293FT cells are modified to generate high-yield lentiviral titer.
The PC3-mm2 cell line was a gift from Dr. Isaiah J Fiddler, and is a highly metastatic
derivative of PC3 cells.
The C4-2B4 a cell line derived from LnCap cells that metastasized to lumbar spine
region were a gift from Dr. Sikes (University of Delaware, Delaware)137. C4-2B4/Cad11 cell
line was previously generated as described in Huang et al47.
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Patient Derived Xenografts (PDX)
The xenograft samples MDA-PCa 133-4, 180-30, 183, 118b, 144-13, 146-10, and
155-2 are sublines generated using primary castration-resistant prostate carcinomas acquired
during palliative surgical resections at The University of Texas MD Anderson Cancer Center
to implant into immune compromised mice124. The MDA-PCa 144-13, 146-10, and 155-2
were derived from patient prostate and have been characterized as small cell prostate
carcinoma (SCPCa) 9, 124. The MDA-PCa 118b, 133-4, and 183 sublines are derived from
patient bone metastatic lesions and have previously been characterized as adenocarcinomas
(AdenoCa)36, 63, 124. The MDA-PCa 180-30 xenograft was derived from the
cystoprostatectomy of a Gleason 9 (4+5) patient who relapsed despite receiving maximum
androgen blockade and docetaxel-carboplatin combination therapy114. cDNA from these
patient derived xenografts were obtained from the laboratory of Dr. Sankar Maity for qPCR
using SYBR green. p80 and p130 specific primers were used to look at the differential
expression of the AMOT isoforms in the different xenografts (Table 1).

Plasmids

Bacterial Expression

The vector pGEX4T-1 was used to generate GST-tagged fusion proteins expressed in
Escherichia coli (E. coli). The vectors pET28a and pET28b were used to generate His-

25

tagged fusion proteins expressed in E. coli. The Amot-p80 cDNA in the pCR4-TOPO vector
was purchased from Open Biosystems (Pittsburgh, PA).

Mammalian Expression

The vector p3xFlag-CMV10 was purchased from Sigma-Aldrich and used to generate
3x-Flag-tagged fusion proteins.

The v180-Flag (p80-Amot-3xFlag), Amot mutant 1

(pΔBAR-Flag), Amot mutant 3 (pBAR-flag), Amot mutant 5 (p∆EYLI) and pEYFP (AmotYFP) vector set were gifts from Dr. Clark Wells (Indiana University, Indiana). A different
set of Amot deletion mutants, Amot mutant 4 (pCMV-Flag-p80-CC), Amot mutant 2
(pCMV-Flag-p80-∆CC) and the p130/Amot (p130-Amot -3xflag) were gifts from Dr. Joseph
L. Kissil (The Wistar Institute, Pennsylvania). The retroviral vectors pBMN-I-GFP and
pBMN-I-Neo were used to generate stable cell lines were previously described in Huang et
al47. The lentiviral vectors for shRNA pLKO and pGIPZ were purchased from Thermo
Scientific (Waltham, MA).

Construction of retroviral vectors

The bicistronic retroviral vectors pBMN-Amot-his7-GFP and pBMN-Amot-his7-Neo
were constructed by inserting Amot-his7 cDNA into pBMN-I-GFP or pBMN-I-Neo through
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BamHI and NotI sites.

The bicistronic retroviral vector pBMN-Cad11ΔAmot-GFP was

constructed by PCR using pBMN-Cad11WT vector as the template using the primers Cad11EC-forward and CBS-10-reverse (Table 1). The resulting PCR product was subcloned and
its sequence verified by DNA sequencing. The Cad11-∆Amot cDNA was isolated from
pCR2.1 and subcloned into the pBMN-I-GFP or pBMN-I-Neo vectors. The Cad11-Δβcat
insert was constructed using the Stratagene Site-Directed Mutagenesis Kit and the primers
(∆βcat-Forward and ∆βcat-Reverse) listed in supplemental Table S1, using Cad11-WT as the
template. The resulting product was verified by DNA sequencing.
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Table 1. List of Oligos. Above are the names and sequences of the oligos and oligo pairs used
to complete this study. The last column describes the use of the oligo or oligo pair.
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Generation of GST-Amot or Amot-his7 proteins

cDNA for GST-Amot or Amot-his7 fusion protein was generated by PCR using
pCR4-TOPO-Amot as template using primers Amot-F1 and Amot-R1 (Table 1). The PCR
product was ligated into the pCR2.1-TOPO vector and the DNA sequence was confirmed by
using a series of forward Amot oligos, Amot F2 to F4 (Table 1). The Amot insert was
removed from pCR2.1-p80-Amot via digestion with BamHI and NotI endonuclease enzymes.
The resulting insert was then subcloned into the pGEX4T1 or pET28b vectors to express
Amot as a GST or his7 fusion proteins, respectively, in E. coli. GST-Amot or Amot-his7
protein was purified using Thermo Scientific glutathione-agarose (Waltham, MA) or Qiagen
Ni-NTA agarose (Vinlo, Limburg), respectively.

Antibodies

The polyclonal antibody (pAb) goat anti-Amot (L-16) against a C-terminal peptide
was purchased from Santa Cruz (Santa Cruz, CA). Anti-Flag antibody was purchased from
Sigma-Aldrich. Monoclonal antibody (mAb) against the C-terminus of Cad11 (5B2H5) was
purchased from Invitrogen (Invitrogen, Carlsbad,CA). Generation of mAb 2C7, an antibody
against the extracellular domain of Cad11, was described in Lee et al 64.
Polyclonal and monoclonal anti-p80-Amot antibodies were generated as follows.
Purified GST-Amot protein was used to immunize rabbits for generating polyclonal anti-
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Amot antibody and mice for generating both polyclonal antibodies (mouse sera) and
monoclonal antibodies. Rabbit anti-Amot antibody was affinity purified as follows. Freshly
purified Amot-his7 protein was allowed to dry on a strip of nitrocellulose membrane, which
was then incubated with the rabbit final bleed overnight at 4°C. The nitrocellulose strip was
washed to remove nonspecific protein present in the rabbit bleed and the Amot antibodies
were eluted using Gentle Elute elution buffer (Thermo Fisher).

Construction of the cadherin cyto GST proteins

The cytoplasmic domain (cyto-domain, amino acids 641-796) of human Cad11 was
amplified by PCR using full-length human Cad11 as a template. A GST fusion protein
expressing two copies of Cad11 cyto domain was constructed as follows. Two fragments of
cyto-domain with different restriction enzyme sites were generated. The first fragment,
which includes four glycine residues at the C-terminus, was amplified by using primers
EcoRI-BamHI-cyto-F and EcoRI-cyto-R (Table 1). The second fragment was amplified by
using primers EcoRI-BamHI-cyto-F and NotI-cyto-ter-R (Table 1). After the PCR reactions,
the cyto-domain1 DNA fragments were subcloned into the pCR2.1-TOPO TA vector
(Invitrogen, Carlsbad, CA).

After confirming by DNA sequencing, the cyto-domain1

fragment was isolated from pCR2.1-cyto-domain1 plasmid by digesting with BamHI and
EcoRI. The second fragment was isolated by digesting pCR2.1-cyto-domain2 plasmid with
NotI and EcoRI. These two DNA fragments were ligated with the pGEX-4T-1 plasmid
through BamHI and NotI restriction sites to generate plasmid pGEX-Cad11-cyto-2X. The
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pGEX-E-Cad-cyto-2X,

pGEX-Cad11∆JMD-cyto-2X

and

pGEX-Cad11∆CBS-cyto-2X

containing two copies of E-Cad cytoplasmic domain and mutant Cad11 cyto domains
respectively, were constructed similarly. We then used the cyto-2X constructs to create
Cad11-cyto-WT, Cad11-cyto-∆JMD, and Cad11-cyto-∆CBS GST fusion proteins expressing
single copies of wild-type or mutant Cad11 cyto-domains as described in Huang et al47. The
serial deletion mutants within CBS domain were generated using pGEX-Cad11-cyto
construct as a template and using the reverse primers listed in Table 1, which delete every ten
amino acids from the C-terminus. p3xFlag-Cad11-cyto-2X was generated by restriction
digestion of pGEX-Cad11-cyto-2X and subcloned into p3xFLAG-CMV (Sigma-Aldrich, St.
Louis, MO) through HindIII/NotI sites (New England Biolabs, Inc. Ipswich, MA).

These

constructs were generated by Dr. Mehmet Asim Bilen.

Isolation of proteins associated with Cad11 cyto domain

GST-cyto constructs were expressed in E. coli and the induced protein was purified
through glutathione-agarose. C4-2B4 cells were scraped from plate in cold distilled water
with protease inhibitors and homogenized with a Dounce homogenizer. The cleared lysate
was mixed with GST-E-Cad-cyto-2X protein immobilized on glutathione-agarose beads on a
rocker at room temperature for 2 hrs. The beads binding E-Cad cyto-2X protein were
removed and the supernatant was mixed with GST-Cad11-cyto-2X protein immobilized on
glutathione-agarose beads at 4 oC overnight. The proteins bound to GST-E-Cad-cyto-2X and
GST-Cad11-cyto-2X were resolved on a 4–12% gradient NuPage gels (Novex, San Diego,
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CA). The gel was stained with GelCode (Thermo Fisher) and the proteins associated with
GST-Cad11-cyto-2X were identified by mass spectrometry.

Direct protein interaction assays

Purified Amot-his7 protein was incubated with GST(-), GST-E-Cad cyto-2X, GSTCad11-cyto-2X or GST-Cad11-ΔCBS-2X in TBS with 0.1% Triton X-100 overnight at 4°C
with rocking. The flow-through was removed and the beads were washed three times using
TBS with 0.1% Triton X-100. Proteins eluted from the beads were examined by western blot
analysis using a mouse anti-Amot mAb.

Transfection of mammalian cells

HEK293T

were

transfected

with

mammalian

expression

vectors

using

polyethylenimine (PEI) as previously described31. After 48 hrs, the transfected HEK293T
cell lysates were used for GST pull-down assay.

Immunoprecipitation Assays

Cells were washed twice with ice-cold PBS with 50mM CaCl2 and 50mM MgCl2
(PBS/+CaCl2/+MgCl2). The cells were then lysed in buffer containing 50 mM Tris pH7.2,
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150mM sodium chloride (NaCl), 1mM sodium orthovanadate (Na3VO4), 50 mM sodium
fluoride (NaF), 25 mM β-glycerophosphate, protease inhibitors, and 1% Triton X-100 and
processed as described above for the isolation of Cad11 interacting proteins. The cleared
lysates were incubated with antibody for one hour. Then protein G- and A-agarose beads
were added to each reaction tube and incubated for two hours at room temperature with
rocking. The agarose beads containing the protein-antibody complexes were washed four
times with ice-cold PBS/+CaCl2/+MgCl2. The protein-antibody complexes were analyzed on
a SDS-PAGE for western blot analysis.

Viral Infection

Lentivirus

293FT cells were transiently transfected with pGIPZ vectors expressing shRNA with
a scramble sequence or target sequence along with the viral envelope vector pCMV-VSV-G
and the packaging vector pCMV-dR8.2 using PEI. After 48hours of PEI transfection, the
cell culture media with lentivirus titer is collected and filtered through a .45μM filter to
remove 293FT cells.

Polybrene was added to the filtered lentivirus titer to improve

transduction to the target cells. Target cells were infected until at least 30% of cells express
GFP from the pGIPZ vector. The cells are then selected using the antibiotic puromycin
(puro).
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Retrovirus

These retroviral vectors were transfected into Phoenix cells using PEI transfection.
After 48 hours, the culture media were collected for infection of mammalian cells as
described previously 70.

Generation of C4-2B4 cells overexpressing Cad11 mutants

To express Cad11 wild type (WT), Cad11-∆Amot, and Cad11-∆β-cat in C4-2B4
cells, cells were transduced with recombinant retroviruses with GFP or Neo selection marker.
GFP positive cells were selected by fluorescence activated cell sorting (FACS) and Neo
positive cells were selected using the antibiotic G418, also known as neomycin (Neo).

Generation of PC3-mm2 cells with knockdown of endogenous Cad11 followed
with expression of Cad11 mutants

PC3-mm2 cells were transduced with Cad11 shRNA in the lentiviral vector pLKO.1puro (TRCN0000303363 NM_001797.2-3233s21c1, Sigma).

The shRNA sequence is

located at the 3’-untranslated region. shRNA transduced PC3-mm2 cells (PC3-shCad11)
were selected by puro. PC3-mm2 cells transduced with a control pLKO.1-puro vector (PC3sh-vec) were used as a control.

PC3-shCad11 cells were then transduced with Cad11
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mutants in bicistronic retroviral vectors and the transfectants were selected by FACS based
on GFP.

Fluorescence-Activated Cell Sorting (FACS)

To sort cells expressing the pBMN-I-GFP constructs, cells from a subconfluent 10cm plate were lifted using trypsin digestion. The cells were washed with RPMI/10% FBS to
neutralize and remove the trypsin. Then the cells were sorted on a FACScan analyzer
(Becton–Dickinson, California). Cells that were positive with green fluorescence were
collected, washed with RPMI/10% FBS, and plated on 10-cm tissue culture plates.
For analyzing Cad11 cell surface expression, cells from a subconfluent 10-cm plate
were released from the plate using the non-enzymatic Cellstripper solution (Cellgro,
Virginia). The cells were resuspended in DMEM/10% FBS and incubated with normal IgG
or 2C7mAb as primary antibody for an hour. The cells were then incubated with the
AlexaFluor 488 secondary antibody before sorting on a FACScan analyzer (Becton–
Dickinson, California). Cells that were positive for 2C7 binding were positive for Cad11
membrane expression.
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Immunofluorescence staining

Cells were plated on glass coverslips to 70% confluency. The adhered cells were
washed with PBS before fixed with ice-cold methanol for 10 minutes at -20°C.

The

methanol was removed and the cells were allowed to dry. The cells were then re-hydrated
with PBS and solubilized with 0.2% Triton in PBS. After the solubilization step, cells were
washed three times with PBS before blocking in PBS with 5% normal donkey serum and
0.05% Triton for an hour at room temperature with rocking. The primary antibody was
diluted in blocking solution and incubated on the cells at 4°C with rocking overnight. The
cells were washed with PBS before incubating with secondary antibody. After secondary
antibody incubation, the cells were washed and incubated with DAPI staining.

Migration Assay

PCa cells (1 × 105 cells) suspended in serum-free media were seeded in the upper
chamber of FluoroBlok migration inserts47. The lower chamber contained media with 10%
FBS. After incubation for 8 hours, the migrated cells in the bottom part of the insert were
labeled with calcein AM. Values for migration were expressed as the average of migrated
cells per microscope field (×100). Five microscopic fields per insert were counted. The 8
hour migration time was used to avoid the possibility of proliferation affecting the assay
results.
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Aggregation assays

L-cells (CCL1.3) expressing empty Neo vector, Cad11-WT, Cad11-ΔAmot, or
Cad11-Δβ-cat were generated via retrovirus infection. Control L-vector cells express only
Neo. The cells were released from culture plates using Cellstripper (Cellgro, Virginia) for 10
to 12 minutes at 37°C, suspended in DMEM with 10% FBS, mixed on a rocker, and counted
using a hematocytometer. Cell clusters containing 3 or more cells were considered as
aggregates as previously described in Lee et al. 64.

Statistical analyses

Student’s t test (two-tailed, paired) was used for statistical analyses. A P-value of less
than 0.05 was considered statistically significant. Data are expressed as the means ± SD
unless otherwise specified.
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Chapter III: Identification of Amot as a novel Cadherin-11 interacting
protein

Chapter III, Section I: Identification of Cadherin-11 interacting proteins

Rationale
A previous study found that expression of Cad11 in PCa cells increased cell
migration in vitro and metastasis to bone in vivo30, 47. Further in vitro experiments showed
that the aberrant expression of Cad11 in PCa cells facilitated interaction between PCa cells
and osteoblasts47, 64. We found that Cad11 enabled PCa cells to invade into a monolayer of
osteoblast cells and Cad11 expression also increased the migration and invasion capacities of
PCa cells47. We also found that the juxtamembrane (JMD) and the β-catenin binding (CBS)
subdomains of the Cad11 cytoplasmic tail are critical to Cad11-mediated cell migration and
invasion47.

The results suggested that the cytoplasmic domain is involved in signal

transduction to modulate Cad11 function.

Though Cad11 binds common cadherin

interacting proteins, such as p120-catenin (p120) and β-catenin (β-cat), like E-Cad, Cad11
has opposing functions to E-Cad and a different tissue expression pattern compared to other
mesenchymal cadherins. We, therefore, suspected that Cad11 could interact with a unique
subset of intracellular proteins to participate in Cad11-mediated functions, which may
contribute to the progression of PCa and PCa metastasis to bone.
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Results
Expression of mesenchymal cadherins during cancer progression has been noted to
result in increased cell migration and invasion, while the expression of E-cad in cancer cells
suppresses these effects77. To identify the Cad11 interacting proteins that mediate PCa cell
migration and/or invasion, a subtractive approach was used. The cytosolic fraction of the
PCa cell C4-2B4 was incubated with agarose beads binding GST-E-Cad to deplete common
cadherin-interacting proteins (Fig. 7A). The E-Cad depleted lysate was then incubated with
GST-Cad11 beads to identify proteins that uniquely interact with the Cad11 cyto (Fig. 7A).
Incubation with GST-E-Cad was able to remove the common ‘classic cadherin’ interacting
proteins, such as p120) and β-cat (Fig. 7B). The beads were resolved on SDS PAGE and the
area designated by the bold line was excised for mass spectrometry analysis (Fig. 7C).
Mass spectrometry analysis identified Amot as a novel Cad11 interacting protein
(Table 2). The peptides sequenced by mass spectrometry correspond to Amot and not the
other members of the Motin family, i.e. AmotL1 or AmotL2 (Fig. 8A). As previous studies
showed Amot plays a role in cytoskeleton organization and endothelial cell migration35,
Amot was chosen for further study as a candidate for mediating Cad11 functions in PCa
cells. To confirm Amot is indeed a unique Cad11 interacting protein, C4-2B4 cytosol was
incubated with either GST-E-Cad or GST-Cad11.

We found that in two separate

experiments, Amot was able to bind to the GST-Cad11 fusion protein but not the GST-E-Cad
fusion protein (Fig. 8B). To further show Amot is a specific Cad11 interacting protein and
that this interaction requires no adaptor protein from the C4-2B4 cytosol, bacterially
expressed Amot was incubated with GST, GST-E-Cad, or GST-Cad11. We found that Amot
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binds directly and specifically to Cad11 (Fig. 8C). Together, these data suggest Amot may
indeed be a Cad11-specific interacting protein.
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Figure 7. Isolation of Cad11 specific interacting proteins. (A) Schematic of GST fusion
proteins used to isolate cytoplasmic proteins that uniquely interact with Cad11. (B) Western blot
analysis showing GST-E-Cad incubation removes common ‘classic cadherin’ interacting proteins.
(C) Coomassie stain showing GST-Cad11 eluted proteins for mass spectrometry analysis.
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Accession
Number

Protein Name

# Peptide
(Score)

MW

gi|4502599

Carbonyl reductase 1

7 (507)

30,375

gi|7108915

Eukaryotic translation elongation factor

5(284)

46,269

gi|5729877

Heat shock 70kDa protein 8 isoform 1

3(160)

70,897

gi|340219

Vimentin

2(149)

53,713

gi|194384250

HSP70 1A variant

2(147)

43,002 or
70,000

gi|22671723

Putative NFκB activating protein

3(128)

103,919

gi|37492

Alpha-tubulin

2(122)

50,157

gi|35959

Tubulin 5-beta

2(91)

49,630

gi|19111150

Angiomotin

2(84)

72,539 or
118,084

gi|115206

C-1-tetrahydrofolate synthase

1(74)

101,558

gi|219588

DnaJ protein homolog (Hsp40)

1(63)

44,877

gi|307141

Lysozyme precursor, chain A

1(59)

16,555

gi|119594429

Eukaryotic translation elongation factor 1 gamma, isoform 1(44)
CRA_a

36,405

gi|16933557

Dachsous 1 precursor

346.177

1(42)

Table 2. Mass Spectrometry Analysis Results. Amot was identified as a Cad11 interacting protein.
Through literature search, we found Amot shared a Cad11 function, i.e. cell migration. Thus, Amot
was considered the most suitable candidate for further study.
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Figure 8. Identification of Amot as a Cad11-specific interacting protein. (A) The
peptides identified in the mass spectrometry analysis are highlighted in red. (B) In two
separate experiments incubating C4-2B4 cytosol with GST-E-Cad or GST-Cad11 cyto
proteins, we found Amot binds only to GST-Cad11. (C) Purified Amot protein was
incubated with the GST fusion proteins to show that Amot binds specifically and directly
to Cad11-cyto.
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Chapter III, Section II: Identification of domains that mediate
Angiomotin/Cadherin-11 interaction

Rationale
Classic cadherins express two major cytoplasmic domains that mediate interactions
with intracellular proteins: JMD and CBS. We hypothesized that Amot would bind to one of
these known Cad11 protein binding domains. Therefore, using GST-fusion proteins that
individually delete these domains, we set out to identify the Amot binding domain on the
Cad11 cyto region. Identification of the Amot binding domain would then lend insight to
possible common cadherin-interacting proteins that may be regulating the Cad11/Amot
interaction.
Identification of the Cad11 binding domain on Amot was also needed to understand
the function of the Cad11/Amot interaction. Amot expresses domains that mediate proteinprotein interactions for various functions. Both Amot isoforms contain C-C domains and a
PDZ binding motif (YLI) in the C-terminus. The longer p130 isoform also contains an
extended N-terminal domain with PPxY motifs, which mediates its distinct functions. Flagtagged constructs deleting these known binding domains on Amot were used to identify the
Cad11 binding domain needed to form the Amot/Cad11 interaction. Experiments done to
confirm Amot as a Cad11 interacting protein showed stronger binding of the p80 Amot
isoform in the C4-2B4 cytosolic than p130. We, therefore, expected that the p130 extended
N-terminal would not mediate Amot/Cad11 interaction and that the p80 isoform be the most
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prominent Cad11 interacting protein. We further postulated that Amot would bind
somewhere other than the PDZ motif, thereby allowing interaction with the PatJ/Syx/RhoA
migration complex35, or the C-C domains, to allow Cdc42 or Rac1 activation through the
Amot/Rich1 interaction132, 145.

Results
GST constructs expressing two copies of full-length Cad11-cyto, Cad11-cyto with a
JMD deletion (ΔJMD) or a CBS deletion (ΔCBS) in both copies were used to identify the
Amot binding domain (Fig. 9A). The GST fusion constructs were tested to ensure that p120
and β-cat bind to their respective domains and do not bind when those domains are deleted
(Fig. 9B). As expected, Cad11-cyto-WT-2X was able to bind both p120 and β-cat, while
Cad11-cyto-ΔJMD-2X only bound β-cat and Cad11-cyto-ΔCBS-2X only bound p120 (Fig.
9B). These GST fusion proteins were incubated with HEK293T lysate expressing AmotYFP and we observed that Amot-YFP was unable to bind in the absence of the CBS region
(Fig 9C). To ensure that this binding pattern was due to Amot and not due to change in
protein conformation by the YFP tag or nonspecific interaction with the YFP tag, we
repeated the GST pull-down experiment using HEK293T lysate expressing p80-Amot-Flag.
Again we found that in the Cad11-ΔCBS construct was unable to bind Amot (Fig 9D). To
further show that Amot needed the CBS domain for its direct interaction with Cad11, we
used bacterially expressed Amot-His7 protein to bind GST(-), GST-Cad11-WT, or GSTCad11-ΔCBS and found that the CBS domain is indeed needed to mediate Cad11/Amot
interaction (Fig. 9E).
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The CBS domain expressed by classic cadherins commonly binds β-cat suggesting a
role for β-cat in the Amot/Cad11 interaction or Amot in the β-cat/Cad11 interaction. We
generated CBS deletion mutants to identify the residues that mediate Amot binding to the
Cad11 CBS domain and compare its location to the β-cat binding site within this domain
(Fig. 10A). Cell extracts from HEK293T cells transfected with Amot-YFP were incubated
with the Cad11 CBS mutants. As shown in Fig. 9B, deletion of the last 10 aa from Cad11cyto (Cyto 146-156) resulted in loss of Amot binding, suggesting that the Cad11 CBS
sequence GSKDTFDDDS (Fig. 10D) is involved in binding Amot. Sequence alignment
comparing Cad11 and E-Cad cyto showed that the GSKDTFDDDS sequence is unique to
Cad11 (Fig. 10D). This finding may explain the observation that Amot binds to Cad11-cyto
but not E-Cad-cyto.
β-cat, however, was able to bind to all Cad11-cyto mutants except Cad11-cyto-∆CBS
(1-99), suggesting that the β-catenin binding site is near the aa 100-106 (Fig. 10C). The
corresponding sequence, DSIQIYGYEG (Fig. 10D), coincides with the β-cat binding
sequence determined by E-Cad deletion analysis 139 and by crystal structure studies48. These
observations showed that β-cat and Amot bind to adjacent but non-overlapping sequences in
the Cad11 CBS domain.
We then studied the known Amot protein binding domains to identify the Cad11
binding site. Amot contains two amphipathic helix rich C-C domains, CC1 and CC2, in the
N-terminus and a PDZ binding motif, YLI, at the end of the C terminus123. These domains
are present in both p130 and p80. The extended p130 N-terminus known as the F-actin
binding domain consists of two PPEY and one LPTY motifs
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. A series of 3xFlag tagged
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Amot mutants were transfected into HEK293T cells (Fig. 11A).

The lysates from the

transfected cells were incubated with GST-Cad11-cyto-2X bound on agarose beads (Fig.
11B). We found that Cad11 preferentially binds the p80 isoform than p130 (Fig. 11B),
consistent with the observation in Fig. 6B.

Truncations of the CC1 domain (Mutant 1),

deletions of both CC1 and CC2 domains (Mutant 2), or deletion of the PDZ motif (Mutant 5)
did not affect Amot binding to Cad11-cyto-2X (Fig. 11B). These findings suggest that the
Amot/Cad11 interaction is not through either of the CC domains.

In support of this

possibility, Amot mutant proteins containing only CC1 (Mutant 3) or CC1+CC2 (Mutant 4)
domains were not able to interact with Cad11 (Fig. 11B). These results suggest that Cad11
does not interact with the Amot N-terminus CC domains (Fig. 11C).
As we expected, deletion of the C-terminus PDZ motif or the N-terminus C-C
domains did not affect Cad11 binding. This suggests that though Amot binds to Cad11, the
Amot protein interacting domains are left free to bind to the PatJ/Syx/RhoA migration
complex35 or Rich1/Cdc42 complex132, 145 (Fig 11C). However, deletion of the Amot middle
domain resulted in loss of Cad11/Amot interaction (Fig. 11C). The p80 middle domain has
not been extensively studied. Analysis of the p80 middle domain using the Simple Modular
Architecture Research Tool (SMART smart.embl.de) program did not reveal a recognizable
functional motif and was characterized as low complexity. Thus, we hypothesized Cad11
may interact Amot through an unknown motif in the middle domain.
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Figure 9. Identification of the Amot binding domain on Cad11-cyto. (A) GST fusion protein
constructs. Two copies of Cad11-cyto domain with deletion in the JMD or CBS were inserted after
a GST tag. (B) GST fusion protein constructs tested to show they interacted with respective
common cadherin interacting proteins p120 and β-cat. (C) Lysate from cells expressing Amot-YFP
was incubated with the GST fusion constructs. (n=4) (D) Lysate from cells expressing p80-AmotFlag was incubated with the GST fusion constructs. (n=4) (E) Purified Amot from bacterial
expression was used to show that the CBS domain is needed to mediate Amot/Cad11 direct
interaction. (n=3)

48

Figure 10. Identifying the location of the Amot and β-cat binding sequences
within the Cad11 CBS domain. (A) Diagram of Cad11 deletion mutants within the
CBS domain and summary of Amot and β-cat binding to the deletion mutants. (B)
Deletion of the last 10aa from the C-terminus of Cad11-cyto (Cyto 1-146) resulted in
loss of Amot binding. (n=4) (C) β-cat was found to bind to all cyto mutants except
cyto-ΔCBS (Cyto 1-99). (n=4) (D) Sequence comparison of Cad11 and E-Cad cyto
domains shows that while the β-cat binding motif is conserved between the two
cadherins, the Amot binding motif is not found in the E-Cad cyto domain.
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Figure 11. Cad11 binds to Amot middle domain. (A) Diagram showing the
protein interacting domains in the Amot isoforms and mutant constructs and a
summary of their binding to Cad11-cyto domain. These Amot constructs have 3xFlag tag. (B) N-terminal and C-terminal deletions shown in the top two panels were
compared to wild-type p80-Amot. The pull-down assays with GST-Cad11-cyto-2X
are shown in the bottom two panels. Deleting the known protein binding domains
on Amot did not affect Cad11 binding. Deletion of the middle domain results in loss
of Cad11/Amot interaction. (n=3) (C) A schematic showing the uncharacterized
Amot middle domain binding the last ten residues of the Cad11 CBS domain.
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Chapter III, Section III: Endogenous Angiomotin/Cadherin-11 interaction
within Prostate cancer and non-cancer cell lines

Rationale
Identification of Amot as a Cad11 interacting protein used endogenously expressed
Amot in a GST pull-down assay utilizing a Cad11 fusion protein expressing two copies of
the cytoplasmic region. Subsequent confirmation and mapping assays used overexpression
of Amot or purified Amot protein expressed in bacteria. While these experiments validate
Amot as a candidate Cad11 interacting protein, we needed to test whether these proteins
indeed formed a complex when expressed at endogenous levels in mammalian cells.
Furthermore, previous studies from our laboratory have shown Cad11 is expressed in clinical
samples30; therefore we need to confirm that Amot is expressed in clinically relevant tissue.
We, thus, postulated that endogenous Amot expression is prostate cancer cell lines can form
a complex with Cad11 in immunoprecipitation assays. We further surmised that the p80
Amot isoform is highly expressed in PCa patient derived samples.

Results
We examined the interaction of Amot and Cad11 in mammalian cells. We expressed
two copies of Cad11-cyto in a 3xFlag-tagged vector (Cad11-2X-flag) and Amot-YFP in
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HEK293T. Immunoprecipitation of Cad11 with anti-Flag antibody pulled down Amot-YFP
while control IgG did not (Fig. 12A), confirming that Amot can form a complex with Cad11
in mammalian cells.
We then examined the level of endogenous Amot in PCa cells and HEK293T cells,
which express both p80 and p130. As shown in Fig. 11B, C4-2B4 expressed both p130 and
p80 with levels similar to those found in HEK293T. In contrast, PC3-mm2 expressed very
low levels of Amot that can be seen at a longer exposure time (Fig. 12B).
C4-2B4 cells expressing exogenous Cad11 (C4-2B4/Cad11) were used for
immunoprecipitation (IP) with anti-Cad11 mAb 1A564. p80, but not p130, was found in the
1A5 IP complex (Fig. 12C, top left), consistent with the observation that GST Cad11
constructs preferentially pulled down p80 (Figs. 5B and 11B). Furthermore, IP of Cad11
from PC3-mm2 cells, which endogenously express Cad1130 but very low levels of Amot,
also brought down p80 (Fig. 12C, top right).
Reciprocal IP using affinity-purified polyclonal anti-Amot Abs and C4-2B4/Cad11 or
PC3-mm2 lysates were done to verify Amot/Cad11 interaction. Cad11 was found in the
Amot immune complex from C4-2B4/Cad11 cells and PC3-mm2 (Fig 12D, top). As both
p130 and p80 are expressed in C4-2B4/Cad11 cells, anti-Amot Abs pulled down both Amot
isoforms as expected (Fig 12D, bottom left). In PC3-mm2 cells, which express very low
levels of Amot on Western blot (Fig. 12B), anti-Amot Abs immunoprecipitated proteins with
a molecular mass of approximately 100 and 80 kDa (Fig. 12D, bottom right). It has been
observed that the p130 Amot isoform is susceptible to proteolysis, resulting in generation of
a band around the 100-kD mark5, 100, 129. Thus, it is possible that the ~100-kDa protein
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observed in the Amot immune complex in PC3-mm2 cells may be a p130 breakdown
product. Together, these observations suggest that Amot associates with Cad11 in PCa cells.
To show that the p80 Amot isoform may also play a role in clinically relevant
samples, we use isoform specific oligonucleotides to observe differential expression of the
Amot isoforms in cDNA extracted from PCa patient derived xenograft (PDX) tissue taken
from primary and metastatic sites, and possess a histopathology of either AdenoCa or
SCPCa. We found that the PDX samples express higher levels of the p80 isoform than p130
(Fig. 13). Interestingly, the PDX that have been characterized as AdenoCa have overall
higher AMOT expression compared to PDX characterized as SCPCa (Fig.13). SCPCa is a
rare pathology of PCa with neuroendocrine differentiation, but can often be mistaken for
AdenoCa. Furthermore, we found that the expression level of the Amot isoforms varies
within groups that are either androgen receptor (AR) positive or negative suggesting AR
expression does not affect or is not affected by the expression of AMOT (Fig 13). The
AdenoCa PDX MDA-PCa-118b tumor36, 63 shows almost equal levels of the Amot p130 and
80 isoforms in the absence of functional AR, which is not observed in SCPCa samples,
which may suggest a role of AR in regulating the p80/p130 ratio in the context of AdenoCa
(Fig 13). We also found no correlation between PSA and AMOT levels as MDA-PCa 14413 is derived from a patient who experienced decreasing PSA levels following androgen
deprivation yet still developed bladder outlet obstruction and nodular prostatic mass invading
the bladder9.
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Figure 12. Endogenous Interaction of Amot and Cad11 in cell lines. (A) Mammalian
expression of both Amot and Cad11 was used to show the proteins can form a complex in
mammalian cells. (B) Expression of the Amot isoforms in the cell lines used for our study.
PC3-mm2 has comparatively less Amot than other cell lines that can only be observed at
long exposure or when the protein is concentrated using IP. (C) C4-2B4/Cad11 and PC3mm2 cells were used for anti-Cad11 IP to show Cad11/Amot form an endogenous
complex in PCa cells. (D) The C4-2B4/Cad11 and PC3-mm2 cells were used for antiAmot IP to confirm Amot and Cad11 do indeed form a complex in PCa cells.
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Figure 13. Differential Expression of Amot Isoforms in Patient Derived Xenografts. We
compared PDX cDNA of different PCa type, tissue origin, and AR status to observe changes in
Amot expression and differential Amot isoform expression using qPCR. The data suggests that the
AdenoCa PDX samples have overall more Amot than SCPCa. And that overall, there is more p80
than p130 in most PDX samples despite PCa type, tissue origin, or AR status. qPCR done by Dr.
Yu-Chen Lee, PhD.
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Chapter IV: Elucidating the role of Angiomotin in Cadherin-11 mediated
functions

Chapter IV, Section I: Study the effects of Angiomotin/Cadherin-11 interaction
on Cadherin-11 mediated cell aggregation

Rationale
Previous experiments have shown that expression of Cad11 in L-cells results in
increased cell-cell aggregation64.

This phenotype allows for PCa cell and osteoblast

interaction at the metastatic site47, 64. Moreover, homophilic cadherin interaction plays a role
in collective cell migration and possibly the formation of cancer cell aggregates called
circulating tumor microemboli (CTM) that may aid in survival within the blood circulation40,
46, 119

. In 2013, Oas et al found that the CBS domain on VE-Cadherin was necessary to

maintain cadherin-mediated cell adhesion strength89. However, since the entire CBS domain
was deleted, it is unclear if β-cat binding or another CBS domain binding protein was
responsible for conferring the cell adhesion strength. Bratt et al used CHO cells to show that
as cells reach confluency on a plate, Amot is upregulated and localizes to the cell-cell
junction suggesting a possible role for Amot in strengthening cell-cell interaction21. As
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Amot binds to the Cad11 CBS domain, which is needed to confer cadherin cell adhesion, we
postulated that Amot may play a role in Cad11-mediated increased cell aggregation.

Results
To examine the role of Amot in Cad11-mediated adhesion in cell aggregation, Cad11
with deletion of the 10 aa Amot-binding sequence GSKDTFDDDS located at the very Cterminus (Cad11-∆Amot) or the 10 aa β-cat binding sequence DSIQIYGYEG (Cad11-∆βcat) in the cyto domain was generated and expressed in L-cells (Fig. 14A). Western blot of
L-cells with Cad11-WT, Cad11-∆Amot or Cad11-∆β-cat constructs showed the Cad11
proteins were expressed; however, lower Cad11-∆β-cat levels were observed (Fig. 14B).
Membrane expression of Cad11 proteins was further shown using immunofluorescence
imaging (Fig. 14C). Immunofluorescence analysis showed that both Cad11-WT and Cad11∆Amot were mainly localized at the cell-cell junction in L-cells, consistent with a role of
Cad11 in mediating cell-cell adhesion.

Interestingly, an increase in intracellular

accumulation of Cad11-∆β-cat was observed in L-cells (Fig. 14C). FACS analysis on nonpermeabilized cells using monoclonal antibody mAb 2C7 64 that recognizes the extracellular
domain of Cad11 showed cell surface expression of the Cad11 proteins, but a peak of less
intensity was observed for cells expressing Cad11-Δβ-cat (Fig. 14D). It has been reported
that β-cat plays an important role in membrane targeting of cadherin proteins28. The inability
of β-cat to bind Cad11-∆β-cat may result in the decreased Cad11-∆β-cat expression observed
in Western blot (Fig. 14B), immunofluorescence imaging (Fig. 14C), and FACS (Fig. 14D).
Significant changes in cell morphology were also observed in L-cells transfected with
Cad11-∆β-cat, likely due to a role of β-cat in linking cadherin to cytoskeletal structure32, 89,
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142

. However, there was no observable difference in cell-cell aggregation between Cad11-

WT and Cad11-∆β-cat (Fig 15), though the Cad11-∆β-cat aggregates were not as large and
appeared to be more fragile to agitation. Expression of the Cad11-ΔAmot construct did not
affect cell surface expression/localization or cell morphology. Furthermore, the cell-cell
aggregation assay showed that both Cad11-∆Amot was also able to confer cell aggregation
activity similar to that of Cad11-WT and Cad11-∆β-cat (Fig. 15).

These observations

showed that Amot does not play a role in regulating Cad11-mediated cell aggregation.
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Figure 14. Characterization of L-Cells. (A) Cad11 constructs were made to express wild-type (WT),
ΔAmot, Δβ-cat in L-cells (B) Western blot analysis showed the Cad11 constructs were stably
expressed in L-cells and that these cell lines also expressed Amot. (C) Immunofluorescence analysis
shows the Cad11 constructs localize to the plasma membrane. (D) Flow cytometry also showed that
all the Cad11 constructs are expressed on the cell surface. This figure was completed with the help
of Drs. Guoyu Yu and Song-Chang Lin.
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Figure 15. Amot does not affect Cad11-mediated cell-cell aggregation. (A) Live cell image
comparing the ability of the Cad11 constructs to confer cell-cell aggregation after 3 hours. (B)
A graph quantifying cell-cell aggregation by counting single cells after 3 hours. (n=2) This
figure was completed with the help of Dr. Yu-Chen Lee.
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Chapter IV, Section II: Elucidate the role of the Angiomotin/Cadherin-11
interaction on Cadherin-11 mediated cell migration

Rationale
Expression and function of Amot were first studied in endothelial cells, where it was
observed that the differential expression of the Amot isoforms was necessary for regulating
the various steps in neovascularization during embryogenesis4, 34, 35, 45. Experiments showed
that in the presence of p80 expression, RhoA activity was mainly expressed at the leading
edge of a migrating cell35.

However, when Amot was not expressed, RhoA activity was

dispersed in the periphery of the cell resulting in a stationary cell35. IP analysis showed that
Amot was a necessary component in the PatJ/Syx/RhoA migration complex35. IF analysis
showed Amot localized to adherence junctions but IP and GST pull-down assays failed to
show direct interaction or co-localization with E-cad or vascular endothelial-cadherin (VEcad) 4, 45. Our biochemical analysis found that Amot is able to bind specifically and directly
to Cad11 via a ten residue binding site that is uniquely expressed the Cad11 CBS domain and
is not found in the E-Cad cyto (Fig. 10D). We, therefore, postulated that the Cad11/Amot
interaction may be used to promote Cad11-mediated migration in PCa cells.
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Results
To examine the role of Amot on Cad11-mediated migration in PCa cells, C4-2B4
cells were transduced with Cad11-WT, Cad11-∆Amot, or Cad11-∆β-cat retroviral vectors.
Western blot showed that Cad11-WT, Cad11-∆Amot, or Cad11-∆β-cat proteins were
expressed (Fig. 16A).

Immunoprecipitation of Cad11 proteins in C4-2B4 showed that

Cad11-WT and Cad11-∆β-cat bound p80, while Cad11-∆Amot did not (Fig. 16B). Cad11WT and Cad11-∆Amot bound β-cat while Cad11-∆β-cat did not, as expected (Fig. 16B).
FACS analysis on non-permeabilized cells using mAb 2C7 showed that the Cad11 mutants
were localized at the plasma membrane, although the mean fluorescence intensity of Cad11∆β-cat was lower than that observed in Cad11-WT and Cad11-∆Amot (Fig. 16C).
Immunostaining further confirmed that all three Cad11 proteins were localized on the
plasma membrane in C4-2B4 cells (Fig. 16D). We noted high levels of intracellular Cad11∆β-cat protein, similarly observed in L-cells expressing Cad11-∆β-cat (Fig. 16D).
Interestingly, differences in cell morphology were observed among C4-2B4 cells with Cad11
mutants. The Cad11-∆Amot possesses multiple filopodial projections already suggesting
they may be less motile (Fig 16D). The Cad11-∆β-cat mutants, however, are more bipolar,
which may be more conducive to directional movement (Fig 136D). How these mutations
elicit these morphological changes is not yet clear. It may be that deletion of the Amot
binding site on Cad11 results in loss of the Amot/PatJ/Syx complex to generate a leading
edge resulting in loss of RhoA localization of a single focal point resulting in a flat, stellate
cell with limited migratory potential35. The Cad11-∆Amot cells also appear to stain for
Amot localization near MTOC, which is also a site of RhoA activity suggesting that when
Amot is not bound to Cad11, it may localize to the MTOC135. To test this possibility, the
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FRET analysis done by Ernkvist et al used to observe changes active RhoA localization can
be done using the Cad11 mutants in conjunction with MTOC staining35 . We then examined
the effects of Cad11-WT, Cad11-∆Amot or Cad11-∆β-cat on C4-2B4 cell migration. As
shown in Fig. 16E, Cad11-∆Amot expression significantly reduced Cad11-mediated
migration in C4-2B4 cells compared to Cad11-WT cells.
To further examine the effect of Amot in Cad11-mediated migration, we expressed
Cad11-WT, Cad11-∆Amot, or Cad11-∆β-cat in PC3-shCad11 cells. Western blot showed
that Cad11 knockdown in PC3-shCad11 significantly reduced the endogenous level of Cad11
compared to the control PC3-sh-vec cells (Fig. 17A). The PC3-shCad11 cells with Cad11WT, Cad11-∆Amot, or Cad11-∆β-cat bicistronic retroviral vector containing GFP were
analyzed using Western blot to confirm Cad11 expression (Fig. 17A).

PC3-shCad11

transduced with empty pBMN-I-GFP was used as a control (PC3-shCad11-GFP) (Fig. 17A).
Immunostaining showed that the Cad11 proteins again localized to the plasma membrane
(Fig. 17B). These cells were then used to study Cad11-mediated migration. Similar to the
observed phenotypes in C4-2B4 cells, re-expression of Cad11-WT in PC3-shCad11 cells
significantly increased the migratory activity compared to PC3-shCad11-GFP (Fig 17C).
Expression of Cad11-∆β-cat in PC3-shCad11 cells also increased migration compared to
PC3-shCad11-GFP (Fig 17C). In contrast, expression of Cad11-∆Amot did not promote the
migration in PC3-shCad11 cells (Fig 17C).
The Cad11-WT, Cad11-∆Amot, or Cad11-∆β-cat constructs were also expressed in
the non-PCa cells HEK293T, which endogenously express Amot but not Cad11 (Fig. 18A).
Deletion of the Amot binding site abolished Cad11-mediated migration in HEK293T-Cad11
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cells (Fig. 18B), as was observed in PCa cell lines (Fig. 16E, Fig. 17C). Together, these
observations indicate that Amot plays a role in Cad11-mediated cell migration.
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Figure 16. Amot binding needed for Cad11-mediated migration in C4-2B4 cells.
(A) Western blot of Cad11 constructs used to infect L-cells were expressed in C4-2B4.
(B) IP assays were done to test that the deletion mutants were able to interact with the
proteins as expected. (C) FACS analysis showed the Cad11 constructs were
expressed on the cell surface. (D) IF analysis showed the localization of the Cad11
constructs and Amot. (E) Cells (green circles) were suspended in serum-free media
(light blue) within a migration insert placed in serum containing media (purple) for 8
hours before counting the cell that migrated across the insert barrier. The bar graph
quantifies the results of the assay showing that the migration phenotype is lost when
the Amot binding site is deleted (n=4). Panels C and D were done with the help of Dr.
Song-Chang Lin.
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Figure 17. Amot binding needed for Cad11-mediated migration in PC3-mm2 cells. (A)
Western blot analysis showing the knockdown of the endogenous Cad11 and expression of the
new Cad11 constructs. (B) IF analysis shows expression and localization of Cad11 constructs
and Amot in PC3mm2 cells. (C) PC3-shCad11 cells expressing the new Cad11 constructs were
used for a migration assay. The bar graph quantifies the results of the migration assay showing
the loss Cad11-mediated migration when the Amot binding site is deleted. (n=3) This figure was
completed with the help of Grace Liu and Dr. Song-Chang Lin.
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Figure 18. Cad11/Amot mediated migration in HEK293T cells. (A) The Cad11 constructs
were transduced into HEK293T cells and Western blot analysis shows stable expression of
the Cad11 proteins. Expression of Cad11-WT and Cad11-Δβcat also resulted in increased p80
compared to vector and Cad11-ΔAmot. (B) The cells were used to show that in non-PCa cells,
the Amot binding site is needed for Cad11-mediated cell migration (n=2).
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Chapter V: Conclusions

1. Using a protein subtractive method, we were able to ascertain a unique subset of Cad11
cytoplasmic interacting proteins that may aid to elicit Cad11 unique functions in PCa
cells (Table 2).
2. Two peptides corresponding to Amot were identified through mass spectrometry analysis
as a novel Cad11 (Fig. 8A).
3. Biochemical experiments found that Amot bound directly and uniquely to Cad11 and not
to E-Cad (Fig. 8C).
4. The Amot/Cad11 interaction is mediated by the Cad11 CBS domain (Fig. 9C, D, and E).
5. The formation of the Amot/Cad11 complex requires the last ten residues of Cad11 CBS
domain while β-cat binds to the first ten residues of the CBS domain. Thus, Amot and βcat do not share a binding site on Cad11 CBS (Fig. 10B)
6. The last ten residues of Cad11 CBS domain are unique to Cad11 and not found of E-Cad,
which may be why Amot does not bind to E-Cad and also suggests that Amot may not
bind to other classic cadherins (Fig. 10D).
7. Cad11 does not bind to any known and characterized Amot interacting protein domains
(Fig. 11B).
8. Cad11/Amot interaction requires an unknown domain in the uncharacterized Amot
middle domain (Fig. 11B).
9. Amot is endogenously expressed in the PCa cell lines C4-2B4 and PC3-mm2. Though
PC3-mm2 cells express less Amot protein than C4-2B4 (Fig. 12B).
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10. Cad11 and Amot are able to form an endogenous complex in PCa cells (Fig. 12C and D).
11. PDX cDNA samples show p80 expression is greater than p130 overall (Fig. 13).
12. PDX cDNA samples show that AdenoCa samples have more Amot than SCPCa (Fig.
13).
13. Deletion of the Amot and β-cat binding sites on Cad11 CBS do not affect Cad11mediated cell-cell aggregation (Fig. 15).
14. Expression of Cad11-ΔAmot in PCa and non-PCa cells results in loss of Cad11-mediated
cell migration suggesting Cad11/Amot interaction promotes PCa cell migration (Figs. 16
E, 17C, and 18B).
15. The Cad11/Amot interaction is needed to promote Cad11-mediated cell migration, which
may utilize the Amot/PatJ/Syx migration signaling complex observed in endothelial cells
to localize RhoA activity and actin polymerization to the leading edge.

Figure 19. Model for Amot/Cad11 interaction and its role in Cad11-mediated PCa cell migration.
Amot uniquely binds to Cad11 and not E-Cad. This interaction results in promoting Cad11-mediated
migration likely by recruiting the Amot/PatJ/Syx-RhoA activating complex to the cell membrane to
localize actin polymerization where Cad11 is bound.
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Chapter VI: Discussion

Cadherin Switching in Prostate Cancer Cell Migration

The functions of cadherins include but surpass that of cell adhesion alone. Through
homophilic interactions, cadherins establish cellular identity to maintain tissue integrity as well
as coordinate collective cell migration42, 119. The contribution of these functions to the process of
cadherin switching is an important aspect of cell plasticity that mediates key processes during
normal human development, such as the migration of the mesoderm during embryonic
gastrulation42. Similarly in cancer, cadherin switching affects not only the polarity and adhesive
properties of a cancer cell, but also the interaction with its intracellular and extracellular
environment99, 133.
Cancer associated cadherin switching results in the expression of a new cadherin
interacting with a new subset of cytosolic proteins to affect intracellular signaling. This exhibits
changes to cellular morphology and function, such as loss of polarity and increased cellular
migration8, 88, 133. A common cadherin switch in the metastasis of multiple cancers is the E-Cad
to N-Cad switch88. However, PCa metastasis instead seems to rely on the upregulation of the
mesenchymal cadherin, Cad1130, 62. Though PCa cells also express N-Cad, the knockdown of
Cad11 using shRNA was sufficient to decrease cell migration47 and incidence of bone
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metastasis30. Furthermore, targeting the Cad11 extracellular region with a monoclonal antibody
was able to suppress Cad11-mediated metastasis to bone64. Together, this suggests that the
cadherin switch to Cad11, and Cad11-specific interacting proteins, may provide insight into the
mechanism of Cad11-mediated PCa metastasis to bone.
This study identified Amot as a novel Cad11 interacting protein whose interaction plays a
role in regulating Cad11-mediated cell migration in PCa cells. In vitro assays showed that Amot
was able to bind to Cad11 but not E-Cad (Fig. 8B). Further study using bacterially expressed
and purified protein showed the Amot/Cad11 interaction did not require an adaptor protein (Fig.
8C). This novel and direct interaction between Cad11 and Amot provides a molecular basis for
the differences in cell migration and metastatic potential observed in cells expressing Cad11
versus E-Cad.

Because loss of E-Cad expression is a noted characteristic of EMT and

upregulation of Cad11 is needed to promote PCa metastasis133, our study provides one of the
mechanisms in PCa by which cadherin switching promotes cell migration.
How the Cad11/Amot interaction increases cell migration is yet to be determined.
Studies on endothelial cell migration by Ernkvist et al

35

showed that Amot uses its C-terminus

PDZ motif, specifically the sequence EYLI, to bind to the third PDZ domain of the scaffold
protein PatJ. Once Amot binds to PatJ, the guanidine exchange protein Syx is recruited to bind
to the tenth PDZ domain on PatJ to form a signaling complex that regulates endothelial cell
migration by localizing RhoA activity to the leading edge of the cell35. Similarly, Wu et al

136

showed that Amot can also interact with Mupp1, another multiple PDZ domain protein, to recruit
Syx, which activates RhoA to increase endothelial cell migration. Though Amot and PatJ
localize to the plasma membrane, neither have transmembrane domains nor motifs to bind
phospholipids to mediate this phenomenon. So how does the Amot/PatJ/Syx/RhoA signaling
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complex get recruited to the plasma membrane? Herein may be the function of the Cad11/Amot
interaction within PCa cells.
The upregulation of Cad11 during the EMT cadherin switch, the mesenchymal cadherin
could induce recruitment of Amot to the plasma membrane and function as anchor for the
migration complex. Using mutants with deletions of the known protein interacting domains on
Amot, we found that Cad11 binds to Amot through the middle domain, which does not appear to
have known protein binding motifs (Fig. 11). We predicted that Cad11 would not bind to the
PDZ motif, which would allow Amot to continue its known interaction with the PatJ/Syx/RhoA
migration complex35. As we did not find any amphipathic helices in the CBS domain, we did not
expect Cad11 to bind Amot through the C-C domains. Therefore, it is also possible that the
Cad11/Amot interaction may increase migration by leaving the N-terminal C-C domains free to
form the Rich1/Amot complex that could result in activation of a GTPases: Rac1 or Cdc42132, 145.
It has been shown that the Amot/Rich1 complex promotes Rac1-mediated activity132, 145. It is
therefore possible that Cad11 functions to recruit the Amot and its associated small GTPase to
the plasma membrane to create the leading edge of a migrating cancer cell. Further study into
the how Cad11 expression affects RhoA, Cdc42, and/or Rac1 is required.

Cad11 and Small GTPases

The relationship between classic cadherins and small GTPases has been a subject of
study in development and cancer. Studies have shown that the activity of the Rho GTPases
functions not only to induce actin polymerization and microtubule activity in promoting cell
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motility115,

135

, but also actin contraction at focal adhesion sites to stabilize cadherin cell-cell

contact19. Expression of wild-type E-Cad has been shown to promote polarity and impede
cellular migration by reducing the levels of active RhoA and Cdc4210. In addition, N-Cad
expression in neuronal cells is associated with the small GTPase Rap1 in order to orient cell
migration toward the cortical plate53. However, in as much as cadherin expression affects
activity of the small GTPases, GTPase activity also affects cadherin. RhoA activity, for instance,
is suggested to participate in clustering cadherin molecules at the site of cell-cell contact7.
Therefore, understanding the functions pertaining to the relationship between classic cadherins
and small GTPases can lend further insight as to how that relationship varies with Cad11 to elicit
Cad11-specific phenotypes in PCa cells. But the first question would be: what small GTPase is
responsible for facilitating Cad11-mediated PCa cell migration?
There are a few possible small GTPases that could be activated and localized due to
Cad11 expression in PCa cells. As a result of Amot interaction with Rich1145 and the PatJ/Syx
complex35, Amot may serve as an adaptor protein facilitating Cad11-mediated activation of
RhoA, Cdc42, or Rac1 at the plasma membrane to mediate a variety of changes to the PCa cell
cytoskeleton. The Cad11/Amot interaction may recruit active Cdc42 and/or Rac1 to aid in the
extension of filopodia and actin contraction at adherence junctions to facilitate collective
migration, or Rho to induce changes in cell shape and contraction/compaction to aid in extra- and
extravasation18,

19, 43

. Moreover, it is possible that the Cad11/Amot interaction could affect

localization of more than a single small GTPase as Cad11 binds to the middle domain leaving
both the C-C and PDZ domains free to bind to Rich and PatJ (Fig. 11). Considering Rho
participates in actin contraction for stabilizing cadherin adherence cell-cell contacts, could any of
these small GTPases affect Cad11-mediated cell aggregation?
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The small GTPases likely do not affect at Cad11 mediated cell-cell adhesion sites as
observed in other cadherins18. When the Amot binding site was deleted on the Cad11 CBS and
expressed in L-cells, there was no effect on Cad11-mediated intercellular contacts (Fig.15). This
suggests that the Cad11/Amot recruitment of active Rho proteins may only contribute to
migration without affecting cell aggregation for collective migration, or affect binding and
interaction with bone stromal cells. Moreover, it suggests that the Cad11 interaction with JMD
binding proteins, such as p120, and their downstream signaling could remain unaffected.
Studies have shown that p120, a common cadherin interacting proteins, is able to regulate
activity of small GTPases in order to maintain the integrity of the adherence junction through a
variety of mechanisms59. When p120 is bound to the cadherin molecule, it functions to stabilize
cadherin expression on the cell membrane and prevent endocytosis86,

89

. Unbound p120 is

phosphorylated by Src in order to bind and suppress RhoA function59. However, p120 binding to
a small GTPase does not always suggest suppression of activity. In BCa, p120 knockdown
resulted in loss of ErbB2 activation of Rac1 and Cdc42 to induce cell migration52.

This

phenomenon was rescued by ectopic expression of p12052. Moreover, the tumor associated Rac1
splice variant called Rac1b depends on binding p120 to direct cell migration93. The ability of
p120 to suppress RhoA while activating Rac1 and Cdc42 is important in the orientation of cell
migration. RhoA promotes cell retraction to induce cell polarity while suppressing Rac1 derived
protrusions at the leading edge of the cell91. It is possible that p120 suppression of RhoA and
activation of Rac1/Cdc42 results in the establishment of the leading edge24. This suggests there
are conditions in which p120 could function in accordance with GTPases to promote cell
adhesion as well as migration. However, this would depend not only on the small GTPases
recruited by the classic cadherin, but also the p120 isoform expressed by the cell. For example,
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the mesenchymal p120 isoform 1 inhibits Rho activity143 while the epithelial p120 isoform 3 has
no effect, and isoform 4 activates RhoA59.
During cadherin switching, many mesenchymal molecules are upregulated while
epithelial proteins are downregulated, therefore, I postulate two ways in which the cadherin/p120
relationship in this process changes GTPase activity. First, it is conceivable that the E-Cad to
Cad11 switch also changes which p120 isoform is expressed. If this proves to be the case,
identifying which of the p120 isoforms is expressed by PCa cells that express Cad11 will help
understand changes in Cad11-associated GTPase activation. Also, the p120/GTPase signaling
depends on unbound p12059, therefore, it is possible that Cad11 affinity to the expressed p120
isoform will determine what GTPases are inhibited and which are available to mediate changes
to the cytoskeleton. One question is if the Cad11/p120 Rho GTPase signaling has any functional
relationship with the Cad11/Amot Rho GTPase signaling.
The Cad11/p120-mediated signaling of Rho GTPases could affect the Cad11/Amot
signaling in different ways. If Cad11 expressing PCa cells express p120 isoform 3, Cad11/Amot
recruitment of either RhoA via PatJ or Rac1/Cdc42 via Rich1 would not be affected. If the cells
express Cad11 and p120 isoform 4, we may see that the unbound p120 would perhaps further
enhance the Cad11/Amot activation of RhoA. However, if Cad11 is not the only mesenchymal
protein upregulated by PCa cells and the p120 isoform 1 is expressed, the unbound protein may
suppress Cad11/Amot activation of RhoA.

If this is the isoform expressed, the

Cad11/Amot/Rich1 complex in Cad11 expressing PCa cells may instead activate Rac1 or Cdc42.
Another possibility is that Cad11 would maintain p120 binding to prevent inhibition of Rho
GTPase activation via Amot binding. It is important to consider that a cell may express more
than one of the p120 isoforms; therefore localization of the p120 isoforms may also help predict
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what Rho GTPase will be activated in what part of the cell, i.e. Rac1/Cdc42 at the protrusion of
the leading edge and RhoA actin contraction at the lagging end. Therefore, it is important to
examine how these p120 isoforms interact with cadherin molecules to mediate GTPasesignaling.
Something to consider is that Cad11 is not alone in PCa cells. For example, PC3-mm2
cells, which endogenously express Cad11, also express N-Cad. It is possible that Cad11 is
changing Rho GTPase activation in two ways. One way is that Cad11 is able to sequester
cytosolic p120 to maintain cell-cell contact, and to bind Amot for recruitment and activation of
Rho GTPases to induce migration (Fig. 20A). If this is the case, deletion of the p120 binding site
on Cad11, could show a potential change in Cad11/Amot-mediated migration as well as cell-cell
adhesion. As Cad11 relies on binding p120 to stabilize expression on the plasma membrane,
ectopic expression of p120 may be a better method to examine the effects of p120 on
Cad11/Amot functions. The excess unbound p120 would help determine what Rho GTPases
would be active at the cadherin cluster site by competing with the Amot/Rich or Amot/PatJ
complexes for binding to RhoA or Rac1. Another possibility is that Cad11 acts in concert with
other mesenchymal cadherins, such as N-Cad to regulate p120-mediated Rho GTPase activity.
Any unbound p120 would be bound by N-Cad to maintain cell-cell contacts while Cad11 binds
Amot to induce cellular migration (Fig. 20B).
To test this possibility, we would delete the p120 binding site on either Cad11 or N-cad,
or delete the p120 binding site on both to compare changes in Rho GTPase activation. However,
as both cadherins require binding p120 to help stabilize their expression on the plasma
membrane, we could ectopically express p120. Again it would be important to know which
p120 isoform is expressed to anticipate what Rho GTPases will be suppressed or activated.
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Moreover, it would be important to examine the proximity of the Cad11 and N-cad cadherin
clusters induced by GTPase activity as the unbound p120 of either cadherin would affect the
GTPase signaling of the other. Therefore, the affinity between Cad11 and the different p120
isoforms should be compared to that of N-cad in order to better surmise what p120 binds to
which cadherin in order to change Rho GTPase activity. Considering that the cadherin/p120
interaction is regulated through receptor and non-receptor tyrosine kinases59, 72, 73, it would also
be prudent to identify the tyrosine kinases associated with Cad11 in normal and cancerous cells.
It is possible that there is a Cad11-associated kinase that may phosphorylate p120 to increase the
concentration of unbound p120 which may affect Cad11/Amot-mediated GTPase activation (Fig.
20C).
Moreover, it would be of interest to examine if there are any Cad11-specific interacting
intracellular proteins that may enhance Cad11/p120 interaction to prevent p120 phosphorylation
that may increase the concentration of cytosolic unbound p120, which would alter GTPase
activity. Considering Cad11 uniquely binds Amot to mediate the migration function, perhaps
there are other Cad11-specific proteins that help enhance the potency of this interaction by
affecting the interaction between Cad11 and the common cadherin interacting proteins.
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Figure 20. Cadherin-11
regulates cell aggregation
and migration alone or in
conjunction with other
cadherins. (A) Cad11 binds
p120 to stabilize Cad11 at the
plasma membrane and
enhance cell-cell adhesion, as
well as β-cat to tie to actin
cytoskeleton, but also binds
Amot to activate a Rho
GTPase. (B) Cad11 functions
to focus on migration while
another cadherin is
responsible for maintaining
cell-cell adhesion. (C) And
unknown kinase can
phosphorylate p120 to
remove it from Cad11 to
possibly inhibit Cad11/Amotmediated RhoA activation.
Changes in Cad11/Amot
mediated Rho GTPase
signaling will depend on the
p120 isoform expressed by
the PCa cell.

Cell Migration via Cad11 versus Other Cadherins

Members of the Cadherin superfamily mediate multiple cellular functions through
various signal pathways using a variety of intracellular proteins in different cell types and
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cellular contexts117. These interactions are tightly regulated by extracellular and intracellular
changes. Atypical cadherins are able to interact with guanosine nucleotide-binding proteins to
induce intracellular signaling cascades that affect transcription, motility, and secretion8.
Protocadherins, such as Fat and Dachsous, participate in downstream signaling promoting
contact inhibition via the Hippo Pathway74. Though classic cadherins have common interacting
proteins, such as β-cat and p120, they also possess interacting proteins unique to them12, 13, 17, 23,
39, 44, 112, 116, 131, 134

. However, some of those unique interacting proteins function to regulate

cadherin interaction with β-cat or p120.

For example, Xu et al

139

showed that

dephosphorylation of β-cat by PTP1B is required for β-cat binding to N-cadherin. Besides β-cat,
α-catenin and p120, E-Cad has also been shown to interact with presenilin

11

and Hakai37, 96.

What is the function of regulating the stability of the cadherin/catenin complex?
Cell migration through most mesenchymal cadherins is mostly attributed to posttranslational modifications to either the cadherin molecule or β-cat113, 126, 139. For example, Qi et
al found that during transendothelial migration of melanoma cells, N-Cad was tyrosine
phosphorylated resulting in the loss of β-cat binding and release of N-Cad from the
cytoskeleton99. Would phosphorylation of Cad11 or β-cat affect Cad11-mediated migration as
observed in other classic cadherins?
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If Cad11-mediated migration was equally dependent on its dissociation from β-cat to
increase cell motility, cells expressing the Cad11-Δβ-cat construct would have shown a further
increase in cell migration compared to cells expressing Cad11-WT. However, there was no
statistically significant change in cell migration due to deletion of the β-cat binding site
compared to wild-type Cad11 (Figs 16-18).

This suggests that the mechanism of Cad11-

mediated cell migration is unique when compared to other cadherins, thereby requiring a unique
interacting protein to mediate migration.

Furthermore, this Cad11-specific mechanism of

migration may be due to its unique ability to bind Amot, especially since it contains the Amotbinding motif that is absent in E-Cad (Fig. 8D) and the CBS domain of other classic cadherins
(Fig. 21).

Figure 21. The Amot binding site is unique to Cad11. A comparison of the cyto domains of
different classic cadherins shows the ten residues that bind Amot are present only in Cad11.

80

Regulating Cad11/Amot Interaction

Though Amot is expressed as two different isoforms, p80 and p130, they possess distinct
functions. Many of our studies indicate that even when p130 is abundantly expressed, Cad11
preferentially interacts with p80. First, mass spectrometry analysis of Cad11-cyto interacting
proteins identified two peptides that belonged to Amot, not Amot-L1 or Amot-L2 (Table 2 and
Fig. 8A). Then, GST-pull down assays using p130 or p80 expressed in HEK293T cells showed
that Cad11-cyto interacts mainly with p80 (Fig. 11B).

Furthermore, immunoprecipitation

conditions preferentially bound p80, but not p130, co-immunoprecipitated with Cad11 in both
PC3-mm2 and C4-2B4/Cad11 PCa cells (Fig. 12C). How p80 interacts with Cad11 remains to
be determined. Considering the aspartic acid residues in the last ten amino acids of the Cad11
CBS that promote Amot binding, I examined the middle domain for areas rich in positively
charged residues, such as arginine, that may participate to create a salt bridge. A salt bridge
combines two noncovalent interactions, hydrogen bonding and electrostatic interactions, to form
a stable interaction between proteins (Fig. 22).
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Figure 22. Formation of a salt bridge between an arginine residue and an aspartic acid
residue. Interactions between residues of opposite charge result in a combination of electrostatic
and hydrogen bonding that lends stability to the protein-protein interaction.

During optimization of the Co-IP assays, we found higher protein levels of Amot in the
Cad11 IP complex when the lysis buffer contained less than 100mM of NaCl compared to the
standard 150mM of NaCl concentration. Cadherin molecules are known to form salt bridges to
bind β-cat in the first residues of the CBS140, suggesting the possibility the Cad11/Amot
interaction may be mediated by the same noncovalent interactions. This observation suggests the
importance of electrostatic interactions in mediating Cad11/Amot interaction to form a Co-IP
complex. The aspartic acids in the identified Amot binding motif on Cad11 would provide the
negative charge for the electrostatic interaction; therefore, we needed to identify the
corresponding residues that would provide the positive charges within the Amot sequence.
Interestingly, there is a cluster of arginine and histidine residues in the beginning of Amot middle
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domain, i.e. amino acids 337 to 342, 358-365, 404-411, which may contribute to Amot/Cad11
binding.
What regulates Cad11/Amot binding is not yet clear. It is possible that post-translational
modifications such as phosphorylation/dephosphorylation of β-cat or Cad11 are involved in
regulating the binding of Amot to Cad11. Our studies showed that Amot and β-cat bind to
distinct amino acids sequences that are about 40 amino acids apart within the Cad11 CBS
domain. Because the molecular weights of both Amot and β-cat are relatively large, it is also
possible that the proximity of their binding sites may cause steric hindrance and that
Cad11/Amot interaction may be regulated by Cad11/β-catenin status. How Amot binding to
Cad11 is regulated is currently being investigated. However, we must consider that this unique
interaction may be mediated by another Cad11-specific interacting protein. Therefore, we must
also study the interaction between Cad11 and the other proteins identified in the mass
spectrometry analysis (Table 2) that may lend insight into the mechanism of other Cad11mediated cellular functions that contribute to PCa progression and metastasis.

Function of Cad11/Amot Interaction in Development of Bone Metastasis

Cancer metastasis is a multistep process by which cancer cells are able to change their
cellular properties in context with the surrounding tissue architecture and adopt new cellular
functions that allow them to home and colonize a distant site.

Previous studies of Amot
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characterized p80 as an oncoprotein in various contexts. Amot expression enhances endothelial
invasion and stabilize established tubes66. Knockdown of Amot in NF2 mutant cells inhibited
the tumorigenicity of NF2 cells145. Amot was also shown to be upregulated in aggressive breast
cancer and high levels of Amot transcript were correlated with shorter overall survival of the
patients66. Though we did not focus on the tumorigenicity of Amot in PCa, we found Amot
contributed to the metastatic potential of Cad11 expressing PCa cells by promoting cellular
motility (Figs. 16E, 17C, 18B). Therefore, the role of Amot in cancer metastasis may be limited
to cell migration in the context of Cad11.
Previous work showed that expression of Cad11 contributed to the development PCa
metastasis by increasing cell aggregation, increasing migration, and increasing the incidence of
metastasis to bone30, 47. A recent publication from the Lin laboratory by Dr. Yu-Chen Lee et al
found that Cad11-mediated cell adhesion was needed for PCa cells to home and colonize the
bone64. As my deletion studies showed, interaction with Amot did not affect Cad11 intercellular
interaction (Fig. 15) and therefore may not affect the ability of PCa cells to target to the bone.
Together our observations suggest that the Cad11/Amot migration complex may play a role in
early stages of PCa metastasis, such as the escape from the primary site or in aiding with
transendothelial migration via changes in Rho GTPase activity and actin reorganization.
However, it would be of interest to observe other functions of Amot that are independent of
Cad11.
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The Amot Mediated Functions in Prostate Cancer

This study focused on the role of Amot in Cad11-mediated functions that promote PCa
progression and metastasis. We found that in PCa cells that express Cad11, Amot is able to
interact with Cad11 to promote cell migration. However, Amot is an adaptor protein that
contributes to a variety of cellular functions through its ability to bind different proteins.
Depending on the cell type and the proteins expressed in that cell type, the resulting Amot
interactions can contribute to cell signaling mechanisms that increase cell migration,
proliferation, and contact inhibition. Therefore, we must examine the Amot in PCa that may be
independent of Cad11 or investigate the possible role of Cad11 in Amot-mediated functions.
The short isoform p80 utilizes its C-C domains to create hydrophobic protein-protein
interactions with proteins, such as Rich1 and Merlin132,

145

. In epithelial cells, the p80/Rich1

interaction is needed to regulate Cdc42 activity in order to establish the apical polarity
complex132. Through the same domain, p80 can bind to the tumor suppressor protein Merlin,
also called NF2145. In Schwann cells, a study showed that Rich1 and Merlin compete for Amot
binding145. Under normal conditions, this interaction functions to suppress cell proliferation, but
there are cases in neurofibromatosis when Merlin is mutated and the failure to bind Amot results
in increased cell proliferation145. Mutation or loss of Merlin in melanoma also enhances cell
proliferation, as well as migration84.

It would be of interest to measure levels of Merlin

expression in PCa cells and how its interaction with Amot or competition with Rich1 affects the
role of Amot in Cad11-mediated cell migration. Though our study showed Cad11 preferentially
bound p80 than p130, the long isoform is still expressed in PCa cells.
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The initial experiments in which Amot was identified as a Cad11 interacting protein
showed that p130 could bind to the Cad11 cyto GST construct (Fig. 8B). Moreover, this
interaction was specific as p130 did not bind to the E-Cad GST construct (Fig. 8B). Though the
interaction is not as prominent as the Cad11/p80 binding, there may still be conditions in which
Cad11 could potentially interact with p130. Therefore, we must also look to examine the
functions of p130 in PCa cells in the presence and absence of Cad11. Much like Merlin, the
p130 Amot isoform has also been found to participate in promoting the Hippo tumor suppressor
pathway. Through the extended 409 aa N-terminal, Amot is able to sequester the transcription
factor YAP in order to facilitate Lats 1/2 mediated phosphorylation147. The extended N-terminal
also contains F-actin binding domains that lends to the p130 function of maintaining cell shape33.
If under certain conditions, Cad11 could bind the p130 Amot isoform, perhaps this
interaction would function to suppress the Hippo pathway and promote YAP nuclear
translocation. Increased nuclear YAP translocation and transcription activity would be of great
use to Cad11 expressing PCa cells. Many of the YAP transcription targets promote not only cell
proliferation, but cell survival as well as secretion of bone morphogenic proteins that may
function to aid in PCa colonization of the bone6,

54

. However, a similar outcome could be

rendered through p80 binding Merlin in order to prevent the formation of the Merlin/Kibra
complex to initiate phosphorylation of Mst 1/2, a key step in the Hippo pathway145. Another
possibility could be to remove p130 binding from F-actin in order to allow changes in the cell
cytoskeleton to further promote cell migration. But what could be a Cad11 independent role of
the p130 Amot isoform in PCa?
The extended N-terminal of p130 contains phosphorylation sites that regulate the p130
protein turnover through ubiquitination and protein degradation129. It would be of interest to
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examine changes in p130 expression during PCa progression and in metastatic lesions. The
cDNA tested from the PDX samples showed that p130 mRNA levels are lower compared to p80
mRNA (Fig. 13). This suggests that p130 may be downregulated in PCa, though analysis of
protein expression would ultimately provide better insight into the functionality of p130 in the
PDX samples. How levels of p130 mRNA and protein are regulated could be used to identify
new potential therapeutic targets.

Diagnostic/Prognostic Marker or Therapeutic Target

Rate of diagnosis for PCa has increased over time due to an increase in the population of
the elderly and also due to the optimization of the PSA test127. The sensitivity of the PSA test
has led to over-treatment of low-risk patients and non-essential radical prostatectomies81, 109, 110.
Studies in proteomics using clinical samples and functional assays are needed to identify
clinically relevant biomarkers that can function to accurately diagnose the stage and assess the
prognosis as to the severity of the disease. Considering that even low levels of Amot are able to
elicit migration in the presence of Cad11 as in the case of PC3-mm2 cells (Fig. 12B), Amot may
not be as good a diagnostic or prognostic marker in PCa. However, examining the co-expression
of Cad11 and Amot in patient samples would give a better gauge of metastatic potential. This is
supported by the data attained using the C4-2B4 PCa cell line, which expresses more Amot than
PC3mm2 (Fig. 12B) but has limited migratory potential until Cad11 is expressed via retroviral
vector (Fig. 16E). Together this suggests that monitoring upregulation of Cad11 expression in
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conjunction with Amot protein expression may serve as a warning that the PCa patient is at risk
of metastasis.
Though the Cad11/Amot interaction may not affect the PCa/osteoblast interaction, we
have yet to understand the conditions which promote Cad11/Amot interaction or what other
functions this complex may possess once in the bone. Analysis of samples derived from primary
tumor or bone metastatic lesions showed that despite changes in AR signaling or PSA levels, the
Amot p80/p130 ratio remains favorable to the p80 isoform in PCa (Fig. 13). Examination of
protein expression in these PDX samples may be warranted prior to elucidating p80 function.
Therefore, investigation of the functional role of Amot in PCa independent of Cad11 interaction
within the bone microenvironment compared to the primary site is warranted.
This study has shown that Amot is a novel Cad11 interacting protein, which functions to
mediate PCa cell migration and may subsequently contribute to the metastatic potency of Cad11
expressing cells.

As the mechanisms that regulate Cad11/Amot interaction are yet to be

identified, it would be premature to suggest an agent that may target and inhibit this interaction
or at what stage in the disease inhibiting the Cad11/Amot interaction would be of benefit. Lee et
al found that treatment with an anti-Cad11 mAb (2C7) targeting the third extracellular domain
was able to inhibit cell aggregation and PCa cell/osteoblast interaction thereby reducing
incidence of bone metastasis64. As loss of Amot binding did not affect Cad11-mediated adhesion
or cell aggregation, it is uncertain the effect 2C7 treatment on the Cad11/Amot interaction. In
the paper, the cells were injected into the left ventricle, essentially examining the effects of
Cad11-mediated adhesion on homing and colonization64 rather than dissemination from the
primary tumor site. Since I speculate that the Cad11/Amot interaction may function more in
migrating out to escape the prostate, it would be of interest to inject PCa cells into the prostate
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and then treat with 2C7 to observe changes in Cad11 and Amot expression and function.
However, it may be that 2C7 treatment prevents the PCa/osteoblast interface to suppress PCa
colonization of the bone rather than dissemination from the primary site. Therefore, we would
need to inhibit the intracellular interaction of Cad11 and Amot.
While some protein-protein interactions use large binding surfaces, successful binding of
Amot to the Cad11 CBS seems contingent on ten residues at the very C-terminus of Cad11 that
could pose a challenge as a drug target.

However, recent studies have tackled these

“undruggable” and short binding motifs by designing short peptides that mimic the interface of
protein-protein interaction25, 68. These peptides tend to be small enough and thus permeable to
the mammalian cell membrane68.

Treatments with these peptides do not affect gene

transcription, therefore have minimal impact on non-cancerous cells25, 68. Furthermore, unlike
other small molecule inhibitors that must be administered intravenously, these peptides can be
taken orally since they are metabolically stable68.

As the mechanisms regulating the

Cad11/Amot interaction are not yet known, designs and screening for such a peptide would still
be premature. However, considering the low complexity of the Amot middle domain where
Cad11 binds, it is possible that this may be the most effective method of inhibiting the formation
of the Cad11/Amot complex to prevent PCa cell migration.
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Chapter X: Future Directions

This study, heretofore, has identified Amot as a functional component of the Cad11mediated migration mechanism in PCa. Mutant constructs of Amot and Cad11 identified the
domains that mediate their binding in order to confer the function of cellular migration.
However, the forces that mediate and mechanisms that regulate the formation of the Cad11/Amot
complex are not known. Protein folding and protein-protein interactions are sometimes mediated
by hydrophobic or electrostatic interactions. Protein-protein interaction studies have shown the
importance of post-translational modifications, such as phosphorylation or acetylation.
Furthermore, understanding the mechanisms that mediate and regulate Cad11/Amot interaction
in PCa may be applied to cancers that also express these proteins and have bone tropic
tendencies.
Amot is known to interact with various proteins using hydrophobic interactions via its CC domains. However, analysis of the Amot middle domain showed no further evidence of an
amphipathic helix that could result in another C-C domain to mediate Amot/Cad11 interaction.
To further study this possibility, new N-terminal mutants of Amot were generated to identify the
positively charged amino acids in the middle domain that may form the Amot/Cad11 salt bridge.
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Then site-directed mutagenesis can be used to delete or mutate those residues to show the
importance of this salt bridge within the context of Cad11-mediated migration. Furthermore, the
aspartic acid sequence expressed by Cad11 CBS will be expressed at the tail end of E-Cad to
show that this sequence participates in the formation of a salt bridge to promote Amot/Cad11
interaction.
During optimization of the co-immunoprecipitation (Co-IP) assays to confirm the
endogenous interaction of Cad11 and Amot, we also found that their interaction was better
detected with the addition of sodium orthovanadate in the low salt lysis buffer. The addition of
sodium orthovanadate to the lysis buffer suggested that phosphorylation/dephosphorylation of
proteins are involved in the formation of the Cad11-Amot complex. Post-translational
modifications play an important role in regulating signal transduction pathways.

β-catenin

tyrosine phosphorylation, for example, has been studied to release cadherin from the actin
cytoskeleton resulting in cellular migration12,

141, 142

. Pervanadate treated and untreated cells

prior to lysis will be used for Cad11 and Amot Co-IP experiments to study how changes in
protein phosphorylation regulate their interactions. The tyrosine phosphorylation site of Amot
and Cad11 will be determined by using phospho-tyrosine antibodies and mass spectrometry.
These phospho-tyrosine sites will then be mutated to observe changes in Cad11 and Amot
interaction as well as Cad11-mediated functions in PCa.
Development of osteoblastic lesions results in increased mortality of men with PCa. The
increased osteoblast activity during bone formation results in increased PCa cell survival and
growth. Relieving this aspect of disease burden can increase a PCa patient’s quality of life. To
understand the role of Amot/Cad11-mediated migration in the context of metastasis, the PC3mm2 cell lines generated for Fig. 17 will be used for intraprostatic and intracardial injections.
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An intraprostatic injection will embed the luciferase tagged cells in the mouse prostate to observe
invasion out of the primary site and incidence of metastasis to lymph node or even bone via
bioluminescence. An intracardial injection will introduce the mutant cell lines into circulation
that will allow us to study how the Amot/Cad11 interaction may contribute to PCa extravasation
into the bone microenvironment. Understanding the role of the Amot-Cad11 interaction in cell
migration as well as the regulatory mechanisms that govern it, may aid in the development of
treatments to inhibit their interaction and perhaps prevent PCa metastasis to bone. Furthermore,
independent studies of Cad1167, 97 and Amot51, 100 have shown their increased expression have
been correlated with BCa progression. It is, therefore, possible that the Cad11-Amot interaction
proposed in this study can be applied to BCa and perhaps other bone tropic cancers.
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